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ABSTRACT 
Aim: The objective of study I was to delineate and quantify sex differences in cancer risk and 
survival together with assessing the potential gain achieved by eliminating the excess cancer 
risk in men. Study II and III aimed to in detail characterize the superior non-small cell lung 
cancer survival and the inferior urinary bladder cancer survival, in women, with the 
underlying objective to identify underlying drivers to these two phenomena. In study IV we 
wanted to explore to what extent taller body stature can explain the excess cancer risk in men. 
Methods: All of the studies are Swedish population-based cohort studies. Study I included all 
incident cancer cases (n=872,397) recorded in the Swedish Cancer Register in 1970-2014 at 
age 15-84. The association between sex and cancer risk and sex and cancer survival was 
assessed by estimating male-to-female incidence rate ratios (IRRs) and excess mortality ratios 
(EMRs), respectively, using Poisson regression models adjusted for age and calendar year. 
All incident lung squamous cell carcinoma (n=10,325) and adenocarcinoma (n=23,465) cases 
recorded in the Swedish Lung Cancer Register in 2002-2016 formed the basis in Study II. 
Flexible parametric models were applied to compute adjusted female-to-male hazard ratios 
(HRs) and standardized survival proportions over follow-up, including; age, year, education, 
marital status, birth country, health care region, ECOG performance status, smoking history, 
comorbidity, TNM stage, and tumor location, in the final model. A subgroup analysis of lung 
adenocarcinoma, additionally adjusting for EGFR mutational status, was additionally 
performed. In study III we included all records of urothelial bladder cancer diagnosed in 
1997-2014 at age 18-89 in the Swedish Urinary Bladder Cancer Register (n=36,344). We 
estimated empirical survival proportions and mortality rates in men and women as well as 
female-to-male adjusted HRs and standardized survival proportions, using flexible parametric 
models including; age, year, WHO grade, TNM stage, marital status, education, health care 
region, birth country, and comorbidity, in the fully-adjusted models. In study IV individual-
level information on height from the Swedish Passport Register, the Conscription Register, 
and the Medical Birth Register (n=6,156,659) was linked to the Swedish Cancer Register 
where 285,778 cancer cases were identified. Contemporary mediation analysis was applied to 
assess the effect of male sex, explained by height, on cancer risk. 
Results: In study I we found that men are at a higher risk of 34 of 39 malignancies, and have 
a poorer survival in 27 of 39. Except for smoking-associated malignancies, the excess risk in 
men is stable over calendar time. In male predominant sites, IRRs range from 1.05; 95% CI, 
1.02-1.1 (lung adenocarcinoma) to 8.0; 95% CI, 7.5-85 (laryngeal cancer). Women with non-
small cell lung cancer (study II) are younger, smoke less, and present better performance 
status, compared to men. Women with lung adenocarcinoma additionally present lower 
comorbidity burden, less advanced stage, and more often harbor activating EGFR mutations. 
Women with non-small cell lung cancer have a superior survival that is most consistent in 
lung adenocarcinoma where female-to-male HRs ranged from 0.69; 95% CI 0.63-0.76 (stage 
IA-IIB) to 0.94; 95% CI 0.88-0.99 (stage IIIB-IV). HR estimates remain largely unchanged 
after meticulous adjustments. Except for an unfavorable stage distribution in women, we 
found sparse evidence of sex differences in clinical management or tumor aggressiveness, in 
urothelial bladder cancer (study III). Women, overall, have a poorer bladder cancer survival 
(adjusted HR 1.15; 95% CI 1.08-1.23) which is driven by muscle invasive tumors (adjusted 
HR 1.24; 95% CI 1.14-1.34) and restricted to the first two years from diagnosis. Study IV 
confirmed that a majority of investigated cancers are associated with male sex (here, 33 of 
39) and body height (27 of 39). A fair proportion of the excess male cancer risk is explained 
by taller body stature, and ranges from 0.5% (laryngeal) to 100% (salivary, colon, melanoma, 
and AML). The effect of body height and the mediated effect through height on cancer risk 
are most consistent in cancers with weak or no established risk factors. 
Conclusion: In Study I we found that male sex is a consistent risk as well as a negative 
prognostic factor for a majority of cancers. Identifying and eliminating underlying factors to 
the excess cancer risk in men could substantially reduce the global cancer burden. Men with 
lung adenocarcinoma have a consistently poorer survival that remained largely unchanged 
after adjustments for a range of prognostic factors, indicating sex differences in tumor 
biology (study II). The excess bladder cancer mortality in women is limited to muscle-
invasive tumors, only noticeable within the first two years from diagnosis, and cannot be 
explained by the examined clinicopathological factors (study III). This warrants further 
investigation of sex differences in outcomes and complications to radical cystectomy. A large 
proportion of the excess cancer risk in men is explainable by height (study IV). This finding 
corroborate that a considerable proportion of cancer cases are a result of random processes 
during DNA replication (i.e., bad luck) rather than underlying hereditary and/or 
environmental factors. 
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 BACKGROUND 
1.1 INTRODUCTION  
Patient sex is simple to assess and a persistent predictor of disease risk, treatment response, 
and prognosis in multiple medical conditions, but is still rarely considered systematically in 
the clinical practice (1). Male or female sex are biological traits defined by the karyotype 
46XY and 46XX, respectively, and are reflected by anatomical and physiological differences. 
Gender, on the other hand, indicates different behavior in men and women depending on 
social and cultural context (2). There is no validated tool to assess gender (1, 2). In other 
words, sex considers biological differences like sex hormone levels, reproductive organs, and 
secondary sex characteristics, while gender reflects behavior, including unequal 
environmental exposure and health care utilization (1, 2). Sex and gender are hereafter used 
according to these definitions, but the main focus throughout this thesis will be on biological 
differences between men and women affecting cancer risk and prognosis (2).  
It is well-known that men, compared to women, are both at increased risk of and have a 
poorer prognosis in most malignancies affecting both sexes (3-11). The former has 
traditionally been attributed to gender differences in exposure to environmental risk factors, 
mainly tobacco smoking, alcohol consumption, and occupational carcinogens (12, 13). The 
male survival disadvantage has remained enigmatic, although a common belief is that men in 
general present with more advanced cancer stage at diagnosis resulting in poorer outcomes 
(8). The following section is a literature review with the purpose to give background to and 
motivate the performed studies as well as to justify some of the decisions made regarding 
definitions and stratifications described subsequently.  
1.2 SEX AND CANCER RISK 
1.2.1 Epidemiology 
The excess cancer risk in men is a consistent finding in epidemiological studies and has been 
acknowledged for a long time (3-7, 14). The underlying drivers to the increased cancer 
susceptibility in men have however received less attention. Cancer registers usually report 
results stratified by sex and male sex is commonly mentioned as a risk factor for various 
cancers, without engaging in the rationale behind this phenomenon. Breast and genital cancer 
excluded, men have a higher probability of being diagnosed with a majority of malignancies, 
across geographic region (3, 5, 6, 15). Only a few sites seem to be more common in women; 
biliary, anal, meningioma, and thyroid cancer (3, 5-7). The remaining 30-40 cancers (the 
exact number depends on how finely sites are subdivided) are more common in men. The 
male relative risk for the sites with the largest male overbalance is 2- to 8-fold (Table 1) (3, 5-
7). Even though the male excess risk in general and in particular in sites with a strong 
association to tobacco and alcohol appears to decrease over time, the risk remains elevated 
(5). Some malignancies, including urinary bladder, pleural, and the hematological 
malignancies, present a remarkably consistent pattern over calendar time and unequal 
 2 
exposure to environmental risk factors can hardly explain the male overbalance in these sites 
(3, 5-7). 
There are few comprehensive reports on sex and cancer risk by age. But, the male 
overbalance appears to be present before puberty, increase over age, and culminate in elderly 
when most malignancies peak (5, 7). Anti-oxidative properties of female sex hormones have 
been proposed to protect women from cancer (16). The observed continuous relative risk 
increase in men, many years after female menopause and rapidly declining female sex 
hormones, is inconsistent with this conjecture. Sex differences in cancer risk in children 
(mainly hematological malignancies) can hardly be explained by sex hormones or 
environmental factors since these do not differ substantially in boys and girls. That said, the 
drivers behind sex discrepancies in cancer risk can of course differ in children and adults.  
Table 1. Male-to-female incidence rate ratio (IRR) in cancer sites with the most consistently reported excess male relative 
risk. Data extracted from four publications on sex differences in cancer risk. 
Author, year:   Ashley, 1968 (4)   Cook, 2009 (5)   Biggar, 2009 (7)   Edgren, 2012 (6) 
Geographic region:   
CI5 (60 
countries) 
  SEER-9 (US)   Denmark   
CI5 (60 
countries) 
Calendar period:   1962-1964   1975-2004   1943-2003   1998-2002 
    male-to-female 
IRR1 
  male-to-female 
IRR1 
  male-to-female 
IRR2 
  male-to-female 
IRR3 Cancer site     
Larynx  9.09  5.17  5.82  6.36 
Pleura  -  -  3.87  - 
Esophagus adenocarcinoma  
2.78 
 7.64  
2.92 
 
3.72 
Esophagus squamous cell   2.57   
Lip  11.11  7.16  8.08  4.25 
Urinary bladder  3.57  3.92  3.91  4.12 
Pharynx  2.63  -  3.03  - 
Hypopharynx  -  4.13  -  5.75 
Tonsils  -  3.07  -  3.98 
Lung total   6.67  2.06  2.57  2.08 
Lung squamous cell  -  3.50    - 
Liver  -  2.69  1.95  2.84 
Stomach  2.04  2.19  2.05  2.22 
1Adjusted for age at diagnosis. 2Adjusted for age and calendar year at diagnosis. 3Adjusted for age, gross domestic product, and 
geographic region. 
 
 
1.2.2 Environmental risk factors 
Gender imbalance in exposure to oxidative damage by known carcinogens, like tobacco, 
alcohol, chronic infections, UV/ionizing radiation, and carcinogenic substances including 
chemical agents, pharmaceuticals, food, metals, arsenic, dusts, and ﬁbers (17-23), probably 
explain part of the excess cancer risk men (12, 13, 24). The effect of environmental risk 
factors is manifest for malignancies with a strong association with smoking and alcohol 
consumption, i.e., tumors in the respiratory tract, oral cavity, pharynx, esophagus, and liver. 
The male excess risk of these cancers have declined, but not completely vanished, in 
geographical areas where sex differences in smoking and alcohol consumption have levelled 
out (12). Urinary bladder cancer is closely related to cigarette smoking, but deviate from the 
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general pattern, and the 4-fold relative risk increase in men is remarkably stable over calendar 
time and geographic region (3, 5-7).  
1.2.2.1 Carcinogenic infections 
Cervical cancer is the fourth most common malignancy in women globally and nearly 100% 
is caused by infection with high-risk human papilloma virus (HPV) (23, 25, 26). HPV is also 
associated with squamous cell carcinoma of the oropharynx, anus, and penis. Other infectious 
agents with an established, strong association with cancer include Helicobacter pylori (gastric 
cancer), hepatitis B and C (liver cancer), Epstein-Barr virus (Burkitt, Hodgkin, non-Hodgkin 
lymphoma, and nasopharyngeal carcinoma), human herpes virus-8 (Kaposi’s sarcoma), 
human T-cell leukemia virus-I (leukemia, lymphoma), liver flukes (biliary cancer), and 
schistosomiasis (bladder cancer) (23, 26). Human immunodeficiency virus increase the risk 
of multiple malignancies at various sites mainly through immunodeficiency (23, 26). 
Excluding cervical cancer, there is evidence of a male overbalance regarding the prevalence 
of carcinogenic infections in the general population as well as in cancer patients in total (26, 
27). The fraction of incident non-sex-specific cancer cases attributable to infections are 
estimated to be higher in men (26, 27). This phenomenon may be a result of a lower immuno-
surveillance in men and/or gender-related differences in transmission patterns (26-31). 
1.2.3 Innate risk factors 
Innate, or biological, determinants of sex differences in cancer risk cover anatomic, 
immunologic, hormonal, and/or metabolic differences in men and women.  
1.2.3.1 Stem cell number 
The lifetime risk of cancers of many different types correlates to the total number of cell 
divisions to keep organ homeostasis (32). Larger organs and consequently higher number of 
cell divisions and/or an increased metabolic rate in men compared to women is an interesting 
hypothesis that will be discussed in detail in 1.4 Height and cancer. 
1.2.3.2 Immunology 
Recognition of the role of the immune system in carcinogenesis, cancer immunology, has 
evolved rapidly over the past decades. This interdisciplinary branch spans beyond 
malignancies associated with immunodeficiency conditions and carcinogenic infectious 
agents but is rather concerned with cancer immunosurveillance and immunoediting (33, 34). 
The former is regarded as a host protector property by CD8+ cytotoxic T cells recognizing 
and inhibiting cancer development (33, 34). Immunoediting is a process of interaction 
between the immune system and tumor cells (33, 34). Cancer immunotherapy is the 
application and a category of cancer drugs that acts by directing and/or enhancing the 
immune system to target tumor antigens and attack tumor cells (33, 34). Mounting evidence 
suggests a reduced innate and adaptive immune function in men compared to women (28, 30, 
31, 35). This is likely the underlying reason for the higher relative risk of autoimmune 
diseases in women but also accounts for the increased susceptibility to infections acquired via 
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multiple routes and the reduced vaccine efficacy in men (28, 30, 31, 36). The explanation to 
this anomaly is believed to be due to a trade-off for a selection of sex characteristics affecting 
reproduction (28, 30). With newly gained understandings of the close relationship between 
the immune system and cancer, it is not farfetched to believe that immunological mechanisms 
at least partly account for sex differences in cancer risk as well as survival (28, 30, 31, 36).  
1.2.3.3 Other genetic factors 
Women harbor two copies of chromosome X, but only one copy of each allele is transcribed 
in each cell. Escape from X-chromosome inactivation could result in two copies of tumor 
suppressor genes on the X chromosome, contributing to the lower cancer incidence in women 
(7, 37). The effect of the Y chromosome in disease development and progression, including 
cancer, is unclear (38).  Mosaic loss of chromosome Y is however not a rare event in elderly 
men and appears to be associated with an increased cancer risk (39). Sex hormones and sex-
linked genes have been proposed to affect microRNA which has emerged as a potential 
regulatory molecule in several physiological aspects of disease (40). A study using molecular 
data in cancer patient cohorts from the Cancer Genome Atlas Project discovered extensive 
sex differences in gene expression signatures for some malignancies (41). In addition to 
gender differences in exposure to carcinogens, a different cellular response to oxidative stress 
in men and women have been proposed to contribute to the male cancer susceptibility (42). 
Men also appear to be more vulnerable to low serum concentrations of antioxidants (43).  
1.3 SEX AND CANCER SURVIVAL 
It is important to distinguish between cancer mortality in the population and 
survival/mortality among patients diagnosed with cancer. The former does not only reflect 
prognosis, but also cancer incidence (44). Sex differences in cancer incidence have been 
discussed previously and, to avoid confusion, this section will focus on sex differences in 
cancer patient survival, i.e., mortality after cancer diagnosis. Several partially interacting 
and/or overlapping patient, tumor, and external factors affect cancer patient survivorship. 
Patient characteristics comprise age, comorbidity burden, organ function, performance status, 
cancer-related symptoms, socio-economy, and ethnicity. Commonly used tumor prognostic 
factors include disease stage, within-site primary tumor location, number and location of 
metastasis, and tumor biology (histology, grade, lympho-vascular invasion, proliferation 
indices, and mutational status). Clinical management, like waiting times and treatment 
intensity, additionally affects survival. 
1.3.1 Epidemiology 
Men appear to have a poorer cancer prognosis in a majority of malignancies (8-11, 45).  
Survival inequalities are however not as consistent as when studying incidence. Estimated 
male-to-female hazard ratios for cancer sites with a consistently poorer survival in men, 
extracted from three publications, are summarized in Table 2 (9-11). Comparisons are 
hampered by the fact that different studies use different cancer classification systems with 
varying granularity, effect measures, and methodology. Still, the mortality in men diagnosed 
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with cancer is persistently 10-100% higher, compared to women. Only two sites, biliary and 
urothelial cancer, are typically associated with a poorer prognosis in women (9-11, 45). Few 
studies have reported results over different time scales, but, the female survival advantage 
appears be consistent over calendar time and age, and is most distinct during the female 
reproductive age (8, 46, 47). 
Table 2. Male-to-female excess hazard ratio in cancer sites with a consistently poorer survival in men. Data extracted from 
three publications on sex differences in cancer survival. 
Author, year:   Micheli, 2009 (11)   Cook, 2011 (9)   Jung, 2012 (10) 
Geographic region:   Eurocare-41   Seer-9 (US)   Korea 
Calendar period:   1995-1999   1977-2006   2005-2009 
  
male-to-female 
hazard ratio2 
 
male-to-female 
hazard ratio3 
 
male-to-female 
hazard ratio3 Cancer site    
Thyroid well-differentiated  1.45     1.89 
Skin    1.81   
Skin melanoma  2.04    1.56 
Anus    1.07   
Salivary glands   1.75   1.52     
Hodgkin lymphoma  1.15  
1.20 
  
Non-Hodgkin lymphoma   1.15       
Lung  1.05  1.19  1.32 
Tongue    1.07   
Nasal cavity/sinuses  1.10  1.19  1.35 
Stomach   1.09   1.04   1.01 
1Austria, Denmark, England, Finland, Iceland, Ireland, Malta, Norway, Sweden, Scotland, Wales, Northern Ireland, 
Slovenia, Belgium, the Czech Republic, France, Germany, Italy, The Netherlands, Poland, Portugal, Spain, and 
Switzerland. 2Adjusted for age and region. 3Adjusted for age and calendar year. 
 
 
1.3.2 Patient characteristics 
Advanced age and comorbidity burden obviously affect life expectancy in general but cancer 
survivorship in particular (48, 49). Aging is associated with a decrease in physiological 
reserve, including cognitive, pulmonary, renal, hepatic, and bone marrow function. This 
results in a general frailty and limited tolerance to anticancer therapy, including surgery, in 
elderly (49). Advanced age and comorbidity burden connote an increased number of 
medications and potential drug interactions. History of cardiovascular disease is moreover a 
contraindication to several antineoplastic drugs due to acute and cumulative cardiotoxicity. 
Awareness of the elevated risk of treatment-related complications and toxicity in elderly 
affects cancer treatment decision making and impinges the probability of receiving standard 
of care (48, 49). Information on age is usually available and handled in epidemiological 
studies. There is no general difference in age distribution between men and women diagnosed 
with cancer, though some variation in-between sites do exist. Comorbidity burden is complex 
to measure, impossible to fully adjust for, and is discussed in detail in a separate section 
(3.2.3 Measuring comorbidity) (50, 51). Comorbidity is associated with poorer survival 
directly, but also through decreased cancer treatment intensity and increased treatment-related 
complications. Comorbidity burden, across all age groups, appears to be higher in men and 
sex differences are most evident in cardiovascular and pulmonary diseases and in smoking-
related malignancies (48). 
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Physiological functions affect capacity to tolerate and/or metabolize anticancer treatment and 
could conceivably differ in men and women with cancer (52, 53). There are evidence 
suggesting that the clearance of anticancer drugs, including chemotherapy and monoclonal 
antibodies, is higher in men resulting in more toxicity but also higher efficacy in women (52, 
53). Objective measures of specific organ functions using laboratory, physiologic, and 
cognitive tests, exist but are rarely used in population-based studies due to differences in test 
method, reporting, and variation between laboratories and/or over time. The most commonly 
used score to assess performance status in cancer patients is the Eastern Cooperative 
Oncology Group (ECOG), ranging from grade 0 (fully active and no restriction compared to 
pre-disease) to 5 (dead) (54). ECOG performance status has been shown to correlate with 
response and tolerability to chemotherapy and cancer survival, but is hampered by 
subjectivity, large inter-observer variability, and is also possibly affected by gender 
preconceptions (55).  
The predictive value of cancer alarm symptoms, like hemoptysis, visible hematuria, 
dysphagia, and rectal bleeding, vary between cancer sites and association with cancer 
prognosis is usually stage-dependent. Low socioeconomic status has been shown to impinge 
cancer prognosis (56, 57). The drivers behind this vary between health care systems and 
populations but are probably a combination of risk factor exposure, stage distribution, 
comorbidity, and treatment-related inequalities (56, 57). The excess cancer mortality in black 
populations in the United States conceivably reflects socioeconomic inequalities while the 
survival advantage in lung and gastric cancer in Asian populations is believed to act through 
tumor biology (57). Both are examples of ethnic disparities in cancer outcome (57). 
1.3.3 Tumor factors 
The most widely used staging system for solid tumors is the tumor-node-metastasis (TNM) 
system by the American Joint Committee on Cancer and the International Union for Cancer 
Control (58, 59). The system is based on the size and invasion of the primary tumor (T), the 
extent of regional lymph node involvement (N), and the presence or absence of distant 
metastases (M) (58, 59). Logarithms are used to categorize patients into prognostic groups 
(stage I-IV). Stage I typically implies a small primary tumor (T1) with no lymph node 
engagement (N0) while stage IV connotes the existence of distant metastases (any T, any N, 
and M1). The extent of disease at diagnosis is crucial in treatment decision making and 
prognosis. Women typically present at an earlier stage at diagnosis, but the excess mortality 
in men remains elevated even after adjusting for stage (8-11, 47). Whether the more advanced 
stage at diagnosis in men reflects more aggressive, faster-spreading tumors and/or different 
health care seeking behavior in men and women, is unclear. 
Several biomarkers with either prognostic or predictive value may affect treatment outcome 
and/or prognosis in men and women (49). Left-sided colon tumors are more common in men 
and right-sided in women, malignant melanoma located on the head, neck and trunk is more 
prevalent in men while lower extremities dominate in women (60-62). Men and women 
appear to have different histological distribution within the same anatomical site. Malignant 
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tumors typically harbor abnormal chromosome numbers, which is associated with poorer 
prognosis and seem to be more common in men (63). Free testosterone has been suggested to 
drive cancer aggressiveness and increase cancer mortality in both sexes, the mechanism of 
action behind this association is unclear (64). In colorectal cancer, high levels of 
microsatellite instability (MSI) is not only a positive prognostic factor, but also more 
common in colorectal tumors in women (65, 66).  
The comprehension of the regulating role of immune cells in the tumor microenvironment is 
expanding (33, 34). A more active host immune response to malignant tumors in women 
offers a potential explanation to the female survival advantage (28). See 1.2.3.2 Immunology 
for a more detailed background to immunological mechanisms in carcinogenesis. 
1.3.4 Clinical management 
Initial management of cancer alarm symptoms in primary health care is of vital importance. 
Reduced diagnostic delays can result in cancer diagnosis at an earlier stage and improve the 
chances of long-term cure. A handful of qualitative studies on health seeking behavior have 
been conducted and two meta-analysis synthesizing these results were identified (67, 68). In 
summary, a pattern of longer patient delay among male and socioeconomically deprived 
patients is apparent (67, 69). According to these studies, help-seeking pattern in men appears 
to be negatively affected by fear of embarrassment, weakness, and loss of masculinity (67, 
69). Sanctioning of help-seeking from partners also seems to be more important to men than 
women (67). Gender differences in health care utilization were consistent over different 
cancer sites and geographic areas and it is likely that this phenomenon contribute to sex 
differences in survival, through delayed treatment and more advanced disease stage in men 
(67). Most women in western societies establish a contact to the healthcare system via 
maternity and obstetrics services and screening programs for breast and cervical cancer early 
in adult life. Being acquainted to healthcare from previous experience could potentially lower 
the threshold to seek medical advice when cancer alarm symptoms arise.  
No reports of less optimal cancer care in men compared to women were identified. But 
unequal management could indeed apply to all levels, including sex differences in primary 
prevention and treatment of risk factors, detection of early symptoms, diagnosis, staging, and 
treatment of malignant disease. Reports on gender disparities in medicine rather suggest the 
opposite. Men seem to receive adequate management of myocardial infarctions, are 
prescribed modern, costly cardiovascular drugs, and undergo surgery of liver metastasis, 
more frequently compared to women (70-72). 
1.3.5 Non-small cell lung cancer 
1.3.5.1 Epidemiology and etiology 
Lung cancer is the leading cause of cancer death in Sweden as well as globally (25, 73). 
Small cell and non-small cell lung cancer (NSCLC) are distinct disease entities with different 
clinical characteristics. The major histological cell types comprising NSCLC are 
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adenocarcinoma, squamous cell carcinoma, and large cell carcinoma (74, 75). Women are 
more commonly diagnosed with adenocarcinoma and men with squamous cell carcinoma. 
Lung adenocarcinoma is progressively becoming more common, while the other cell types 
are decreasing. Lung adenocarcinoma is currently the dominating cell type in both sexes in 
most parts of the world, the reasons behind this is not fully understood (76, 77). Despite 
therapeutic advances, NSCLC prognosis has remained poor with 5-year relative survival 
ranging from 17-18% (squamous cell carcinoma) to 18-24% (adenocarcinoma). Tobacco 
smoking accounts for 80% of incident lung cancer cases in Sweden and there is a clear dose-
risk-relationship between tobacco smoking and all of the major lung cancer subtypes, the 
association is moderately weaker in adenocarcinoma (78, 79). Women and young patients are 
more likely to suffer non-smoking associated NSCLC (78). 
1.3.5.2 Symptoms and diagnostics 
Loco-regional lung cancer symptoms include cough, hemoptysis, dyspnea, thoracic pain, 
nerve entrapment, and cardiovascular manifestations. Distant metastases induce symptoms 
depending on location, in lung cancer typically the central nervous system, bone, liver and 
adrenal glands. General symptoms; anorexia, cachexia, fatigue, and fever, indicate advanced 
disease. Most lung cancers are histologically confirmed from needle biopsy or cytology via 
flexible bronchoscopy. Morphological criteria are combined with immunohistochemistry to 
distinguish cell type and determine mutational status. Large cell carcinoma is a diagnosis by 
exclusion. Computed tomography (CT) of the thorax and upper abdomen is used to determine 
TNM stage and positron emission tomography is routine when treatment intention is curative. 
Patients planned for surgery additionally undergo pre-operative pulmonary function tests. 
NSCLC staging relies on the TNM system by the American Joint Committee on Cancer. The 
TNM combination determines stage I-IV, which forms the basis for therapeutic decisions and 
predicts prognosis (58, 80). 
1.3.5.3 Treatment 
Standard treatment in stage I-IIIA (localized disease) NSCLC is radical thoracotomy with 
lobectomy or pneumonectomy followed by adjuvant platinum-based chemotherapy (stage IB-
IIIA). Localized disease in patients unfit for surgery can be treated with hypo-fractioned or 
conventional radiotherapy, depending on tumor size and location. Curative radiotherapy with 
concomitant chemotherapy can be offered to stage IIIB patients in good performance status. 
Palliative radiotherapy can relieve local symptoms and palliative platinum-based 
chemotherapy prolongs life in stage IIIB-IV. Patients with activating EGFR mutations are 
recommended tyrosine kinase inhibitors first line, and EGFR negative/ALK positive tumors 
selective ALK inhibitors second line. Immune checkpoint inhibitors is revolutionizing 
NSCLC therapy, but is so far mainly recommended in second line advanced NSCLC (81, 82).  
1.3.5.4 Prognostic factors and sex 
Known prognostic factors in NSCLC include TNM stage, tumor biology (histology, 
differentiation grade, proliferation rate, pleural and vascular invasion, mutational status), 
  9 
primary tumor location, number of resected lymph nodes, number and location of metastasis, 
age, smoking history, socioeconomic status, ethnicity, comorbidity, performance status, and 
presence of pulmonary symptoms and weight loss at diagnosis (83-94). Multiple studies from 
separate geographic regions have concluded that male sex is an independent, negative 
prognostic factor in NSCLC (83, 84, 86, 93, 95-105). Women are more often diagnosed with 
lung adenocarcinoma, having a slightly better prognosis per se, and several studies have 
noted that the female survival advantage seems to be limited to this cell type (100, 102-104, 
106-109). Moreover, men with NSCLC have an unfavorable stage distribution, comorbidity 
burden, more often smoke, and are older at diagnosis, compared to women (86, 87, 98, 110-
113). The perioperative mortality in men with NSCLC has been reported to be 4-fold 
compared to women, possibly reflecting unaccounted comorbidity in male patients (87, 107). 
Women undergo more partial NSCLC resections with lower risk of complications, 
presumably because of the higher incidence of adenocarcinomas, typically located in the 
peripheral lung tissue, in women. Reports on sex differences in chemotherapy toxicity and 
response rates have been inconsistent (52, 53, 95, 96, 114-117).  
Sex differences in stage can be the effect of gender differences in health care utilization as 
well as an indication of more aggressive tumor behavior in men. Disparities in age, histology 
and smoking patterns in men and women indicate biologic sex differences. Activating EGFR 
mutations are both prognostic and predict response to treatment with tyrosine kinase 
inhibitors in lung adenocarcinoma. EGFR positive tumors are more common in non-smokers, 
Asian populations, and women. Other proposed sex differences in tumor biology include 
hormonal influences and gene expression and polymorphisms affecting DNA-repair capacity, 
p53, GRPR, CYP1A1, GTSM1, ALK, and tumor mutational load (112, 118-121). 
The understanding of the biological rationale behind the observed sex differences in NSCLC 
epidemiology and the possible impact on NSCLC prognosis is improving but many questions 
remain unanswered (120). Many of the listed and discussed prognostic factors overlap, 
interact, and are associated with sex and/or can be hypothesized to affect men and women 
differently. It is indeed a complex task, entailing methodological challenges to disentangle 
the effect of sex from other components affecting NSCLC outcome. 
1.3.6 Urinary bladder cancer 
1.3.6.1 Epidemiology and etiology 
Urothelial carcinoma arises from the transitional epithelium in the urinary tract and 95% 
originates in the urinary bladder (UBC). Urothelial cancer is the 7th most common cancer in 
Sweden and the 9th globally (25, 73). Tobacco smoking is believed to account for 50% of 
UBC (122). Other risk factors include arsenic in drinking water, occupational exposure to 
aromatic amines and polycyclic aromatic hydrocarbons, pelvic radiotherapy, 
chemotherapeutic agents, and (developing regions) urinary Schistosomiasis (123). UBC is 3-
4 times more common in men and mean age at diagnosis is approximately 70 years in both 
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sexes (5, 8, 123, 124). The excess bladder cancer risk in men has traditionally been explained 
by an unequal exposure to carcinogens (smoking and occupational). 
1.3.6.2 Symptoms and diagnostics 
Visible hematuria is the most important alarm symptom and reported in approximately 75% 
of UBC patients. Weight loss, fatigue, anemia, and pain, are symptoms of advanced disease. 
Cystoscopy, transurethral resection of the bladder tumor (TURBT), and histologic 
examination of tumor material, form routine diagnostics (125). CT and/or magnetic 
resonance imaging (MRI) are used for staging (125). UBC is staged according to the TNM 
system by the American Joint Committee on Cancer (58, 126). Tumors are histologically 
classified into low malignant potential (LMP), high (G1), intermediate (G2), and poor (G3) 
cell differentiation (127). 
1.3.6.3 Treatment 
Approximately 75% of the tumors are non-muscle invasive (NMIBC) at diagnosis and 
typically cured after TURBT. Depending on a set of tumor risk factors (T stage, size, number, 
location, histology, radicality after re-resection, vascular invasion, concomitant carcinoma in 
situ) for recurrence or progression, TURBT is followed by intravesical instillations (125). 
The 5-year relative survival in non-metastasized muscle-invasive bladder cancer (MIBC) 
receiving standard of care, i.e., cisplatin-based chemotherapy followed by radical cystectomy, 
is around 50%. Advanced age, comorbid conditions, and impaired performance status in this 
frail patient group impinge capacity to undergo intensive, multimodal treatment and 
conventional radiotherapy forms an alternative in patients unfit for surgery (128, 129). 
Approximately 10-15% of UBC patients present with distant metastasis at diagnosis and have 
a median overall survival of 3-6 months if left untreated (124). First line palliative, cisplatin-
based chemotherapy improves survival, but is associated with severe toxicity, including 
nephrotoxicity (125). Modern immunotherapy is paradigm shifting in urothelial carcinoma 
and several checkpoint inhibitors are now approved for treating advanced disease in Sweden 
(130). 
1.3.6.4 Prognostic factors and sex 
A shorter delay from symptom onset to diagnosis and treatment typically results in less 
advanced disease stage and consequently improved survival (131). Moreover, NMIBC and 
MIBC entail completely different standard of care and prognosis, and also seem to be 
characterized by different genetic and molecular changes (128, 132). Pathologic down-
staging after preoperative chemotherapy is a favorable prognostic marker in MIBC (133). In 
the primary metastatic setting, the so-called Bajorin factors, i.e., ECOG performance status 
≥1 and visceral metastasis, are validated negative prognostic markers (134).  
Unlike the majority of cancers, women with UBC have poorer survival, compared to men (9, 
135, 136). The female survival disadvantage is however not consistent across geographic 
region (137). A register-based study on sex differences in cancer survival in Estonia reported 
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similar UBC stage distribution and survival in men and women (8). Another, Canadian study 
restricted to UBC patients treated with radical cystectomy or radiotherapy, found no sex 
differences in stage, treatment, nor outcome (138). Women with UBC typically present with a 
more advanced stage at diagnosis (139-142). There are evidence that women with visible 
hematuria experience longer diagnostic delays and less frequently undergo imaging according 
to guidelines (139, 141, 142). Importantly, the female survival disadvantage persists after 
adjustment for both stage at diagnosis and treatment modality (135, 139, 140). Women seem 
to suffer from more cisplatin toxicity, the drug of choice in the preoperative and palliative 
setting, whether this affects bladder cancer outcome has not been evaluated (52). Different 
risk factor exposure, metabolism of carcinogens, and sex hormones have also been proposed 
to contribute to the poorer bladder cancer survival in women (141, 142). 
1.4 HEIGHT AND CANCER RISK 
1.4.1 Epidemiology 
The association between adult body height and cancer risk is a well-known phenomenon in 
cancer epidemiology (143-154). Several studies from separate geographical regions have 
concluded that tall stature is associated with an increased risk of cancer overall, site-specific, 
and in both sexes (143-154). The risk appears to increase by 5-15% per 5-10 cm increase in 
body height for most of the studied cancer sites (Table 3) (143, 144, 146, 148).  
A majority of the performed studies on cancer risk and body height have applied a cohort 
approach using cancer register, cause-of-death register, or administrative medical data to 
identify incident cancer cases (143-154). Many studies have been restricted to the most 
prevalent malignancies in the population due to small numbers and low statistical power. In 
combination with lack of information on histological cell type, this has limited the possibility 
to analyze less common subtypes. Ecologic studies imply a different epidemiological 
approach, and a positive association between average adult height and cancer incidence rates 
in different countries has been reported (149). Using death register data to measure cancer 
incidence obviously connotes multiple barriers and calls for cautious interpretations since 
only fatal cases are included and death certificate information is unreliable (152, 154).  
Cancer risk and attained body height are both heavily dependent on socioeconomic status (57, 
155, 156). Previous studies have found the height-cancer association to be remarkably stable 
after adjustments for a wide range of sociodemographic factors (143, 146-148, 151, 152, 
154). Smoking-related tumors (esophageal and head and neck) pose an exception and appear 
to be inversely related to height. In studies containing data on socioeconomic status and/or 
smoking history, tall stature did increase the risk of these tumors in multivariable-adjusted 
models including socioeconomic factors and/or smoking history (143, 146, 147, 151, 152, 
154). The height-cancer association is unexpectedly consistent in malignant melanoma, 
colorectal, kidney, and the hematological malignancies (Table 3).  
 12 
Table 3. Adjusted relative risk (RR) for cancer overall and selected sites, per unit increase in adult body height. Data 
extracted from four publications on body height and cancer risk. 
Author, year:   Green, 2011 (143)   Kabat, 2013 (146)   Sung, 2009 (148)   Wirén, 2014 (144) 
Geographic region: 
  Million Women 
Study (UK) 
  Women's Health 
Initiative (US) 
  
Korea 
  Me-Can (Norway, 
Sweden, Austria)         
Calendar period:   1996-2001   1993-1998   1994-2003   1972-2005 
Sex:   women   women   men women   men women 
   Relative risk1  
/10 cm 
 
Relative risk2  
/10 cm 
 
Relative risk3  
/5 cm 
 
Relative risk4  
/5 cm Cancer site     
Overall  1.16  1.12  1.05 1.07  1.04 1.07 
Malignant melanoma  1.32  1.15     1.13 1.17 
Kidney  1.29  1.23     1.12 1.05 
Colon cancer  1.25  1.14  1.04 1.08  1.09 1.11 
Rectal cancer   1.14   1.26   1.06 1.00   1.06 1.09 
Non-Hodgkin 
lymphoma 
 1.21  1.11     
1.10 1.06 Multiple myeloma  1.13  1.30     
Leukemia   1.26   1.04   1.02 1.21   
1Adjusted for age, region, socio-economy, smoking, alcohol, BMI, exercise, age at menarche/first birth, and parity. 2Adjusted for 
age, alcohol, pack-years, hormone replacement therapy, education, ethnicity, and randomization status. 3Adjusted for age, BMI, 
smoking, alcohol, exercise, salary, occupation, and area. 4Adjusted for date of birth and age. 
 
 
1.4.2 Somatic mutations and cell number 
The rationale behind the height-cancer relationship is debatable and not fully understood. But 
the consistency across geographic region, anatomical site, and sex suggests a common 
underlying mechanism. Somatic driver mutations in cancer occur during DNA replication 
(157). Organ-specific cancer risk is driven by the accumulation of mutations in proto-
oncogenes which in turn is related to stem cell number and turnover rate within tissue (32, 
157, 158). Many mutations occur by chance rather than are caused by extrinsic carcinogens 
or inherited mutations in oncogenes, tumor suppressors, or DNA-repair genes (32, 153, 158-
160). A larger body reasonably consists of more cells and hence connotes a higher lifetime 
risk of developing a malignant tumor. This theorem is supported by the multistage model of 
carcinogenesis (32, 157). The age-incidence pattern, where most malignancies increase 
rapidly with age, is also consistent with the proposed effect of cumulative cell divisions on 
cancer risk (153, 157, 159-161). The exact relationship between height and organ-specific 
stem cell number is however not established and probably differs between organs and cell 
types.  
1.4.3 Other pathways 
Other causative pathways behind the height-cancer association have been outlined. Attained 
adult stature is basically determined by two factors: genes (i.e., parental height) and 
nutritional status during periods of growth; intrauterine, in childhood, and in adolescence 
(155, 156). Body height is a polygenic trait influenced by hundreds of genetic variants in at 
least 180 loci (162). Genetic determinants of height could theoretically promote 
carcinogenesis directly and not through increased cell numbers. Increased environmental 
exposure to carcinogens, for example through a higher basal metabolic rate, might contribute 
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to a higher cancer burden in taller individuals. Caloric intake in adult laboratory animals have 
been found to increase cancer risk (151). Energy expenditure increase with body size but an 
association with energy intake and human cancer is however not yet established. Evading 
apoptosis and thereby enhancing tumor cell survival is an important hallmark in 
carcinogenesis (157). Malnutrition during development do not only entail an increased risk of 
permanent stunting but also lower levels of insulin-like growth factors, a suspect promotor of 
carcinogenesis through down-regulation of apoptosis (152, 158). 
1.4.4 Sex, height, and cancer 
The uniform excess cancer risk in men over calendar time, age, and geographical region, 
described in 1.2 Sex and cancer risk, indicates unknown, non-environmental drivers. Men are 
larger than women in general, and an interesting hypothesis is whether the universal male 
excess cancer risk is explained by a higher number of cumulative stem cell divisions? Walter 
et al explored the relationship between sex, cancer, and height using self-reported data on 
body height from the Vitamins and Lifestyle study, a cohort of approximately 65,000 men 
and women. Incident cancers were identified through the Surveillance, Epidemiology, and 
End Results cancer registries (163). Men had a 50% higher risk of non-sex specific 
malignancies and approximately one third of the male excess cancer risk was explained by 
sex differences in body height (163). This study is to our knowledge the first to explore 
whether the increased cancer susceptibility in men can be explained by body height. 
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 AIMS 
 
The global cancer burden is expanding rapidly, increasing costs for already strained health 
care systems worldwide (164). It is well-known that men, compared to women, suffer an 
increased cancer risk as well as poorer cancer survival. The underlying reasons are however 
not satisfactorily outlined.  
The aims of this thesis are to:  
Study I 
 Delineate temporal and age trends in sex differences in cancer risk and survival using 
high-quality, longterm, population-based data  
 Adress uncharted risk and prognostic factors underlying the disproportionate cancer 
burden in men 
 Quantify the potential gain achieved by eliminating the excess cancer risk in men 
Study II 
 Characterize sex differences in a range of clinicopathological factors, including 
clinical management, affecting non-small cell lung cancer survival 
 Quantify the male survival disadvantage in non-small cell lung cancer using absolute 
and relative effect measures, accounting for various distribution of prognostic factors 
in men and women 
Study III 
 Outline sex differences in clinicopathological factors, comorbidity burden, 
socioeconomy, and clinical management of urothelial bladder cancer 
 Explore if these can explain the poorer outcome in women compared to men with 
bladder cancer 
 Distinguish in which stage group and time-window the excess urinary bladder cancer 
mortality in women occurs 
Study IV 
 Explore the relationship between attained body height and a number of malignancies, 
using large, high-quality, population-based data 
 Quantify to what extent taller body stature, as a proxy for stem cell number and 
cumulative turnover rate, can explain the excess cancer risk in men 
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 MATERIAL AND METHODS 
3.1 MATERIAL 
The numerous Swedish population-based registers constitute a gold mine for epidemiological 
research owing to the governmental bodies responsible for the long-term data collection and 
maintenance (165). The Swedish national registration number (NRN) is a unique identifier 
assigned to all Swedish residents that enables individual-level data linkage between multiple 
registers, and ensures a long-term follow-up regardless of domestic migration (165, 166). The 
national health data registers are state funded and held by the Swedish National Board of 
Health and Welfare who coordinates register linkage in population-based research projects. 
The aim of this section is to give a more detailed background to the included registers and 
register-holders. Exact definitions and management, including groupings, of the included 
covariates are described in the attached publications and manuscripts, studies I-IV.  
3.1.1 The Swedish Cancer Register 
The Swedish Cancer Register (SCR) is maintained by the Swedish National Board of Health 
and Welfare. The overall purpose the SCR is to monitor cancer incidence and survival in the 
Swedish population for health care management and planning, international comparisons, and 
medical research. The SCR prospectively collects data on virtually all incident cancer cases 
diagnosed in Swedish residents since 1958. Not only are malignant tumors included but also 
benign, pre-malignant lesions, as well as conditions of unknown malignant potential. Data on 
basal cell carcinoma is collected in a separate register. Notification of clinical, morphological, 
and autopsy-based cancer diagnoses is mandatory by law which ensures a high national 
coverage of over 95% when validated using the National Patient Register (NPR) (167). 
Reliability is also deemed to be high and roughly 99% of reported cases are morphologically 
verified (168). Some issues still remain, for example under-reporting of malignancies in 
elderly has been noted in cancers with poor outcome from difficult to access anatomical 
locations (i.e., pancreas and lung) (167). To ensure valid comparisons over time, up-to-date 
cancer classification systems are supplemented with the historical revisions. The earliest used 
are the 7th revision of the International Classification of Diseases (ICD-7) for anatomical site 
and the WHO Histological Classification of Neoplasms for morphology (CANC/24.1) (169, 
170). For some cancer sites, refined subdivision is not feasible using the historical 
classification systems, thus explaining why studies of these subtypes are limited to later time 
periods. In addition to medical data (anatomical site, morphology, method and date of 
diagnosis) the SCR comprises linked information on patient (sex, place of residence) and 
follow-up (cause and date of death and date of international migration). 
3.1.2 The cancer quality registers  
Swedish cancer registration is administered by the six Swedish Regional Cancer Centers 
(RCCs) who coordinate the registration, coding, verification, correction, and transfer of SCR 
data to the Swedish National Board of Health and Welfare. The RCCs are also responsible for 
administrating site-specific national cancer quality registers. Clinicians initiated the launching 
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of cancer quality registers for different anatomical sites with the overarching aim to ensure 
equal access to high-quality cancer care irrespective of geographic region in Sweden. The 
quality registers are funded by the Swedish state and county councils. Reporting is not 
mandatory by law but considered a quality measure when comparing clinics and regions. A 
passive patient consent is required but patients can actively opt-out participation. The quality 
registers contain various information on clinical parameters like disease stage, performed 
diagnostic examinations and results from these, first-line treatment, and sometimes also 
follow-up data like treatment response and second line treatment. Steering committees 
consisting of health professionals from the different geographical regions and different 
professional backgrounds cooperate with the RCCs to structure, maintain, and manage the 
cancer quality registers.  
3.1.2.1 The National Lung Cancer Register and the Lung Cancer DataBase Sweden 
The RCC Uppsala coordinates the Swedish National Lung Cancer Register (NLCR). The 
NLCR started in 2002 and aims to include all incident cases of invasive lung cancer 
according to the International Classification of Diseases for Oncology code C34. The NLCR 
does not cover autopsy-detected cases, carcinoma in situ, tracheal, or pleural tumors. 
Coverage is deemed to be high, at approximately 96% compared to the SCR (167, 171). The 
composition of reported variables has varied slightly over the years, but mainly consists of 
diagnostic procedures, staging methods, stage at diagnosis, histopathology, primary tumor 
location, location of distant metastases, mutational status, smoking history, performance 
status, planned treatment, crucial dates (of referral, performed diagnostic investigations, 
primary treatment decision) to monitor waiting times, 1-year follow-up status, and a quality 
of life questionnaire (171).  
Figure 1. The constituting Swedish registers forming the Lung Cancer DataBase Sweden (LCBaSe) 
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The Lung Cancer DataBase Sweden (LCBaSe) was initiated for research purposes and is 
based on all lung cancer cases registered in the NLCR in year 2002-2016 linked, using the 
NRN, to multiple nationwide registers contributing individual-level information like 
comorbidity burden, prescribed drugs, date and cause of death, and socioeconomic variables 
(Figure 1). Please see 3.1.3 Auxiliary national registers for a detailed description of the 
constituting registers. 
3.1.2.2 The Swedish National Register of Urinary Bladder Cancer and the Bladder 
Cancer DataBase Sweden 
Various regional urinary bladder cancer registers started to form in Sweden in the early 1990s 
and in 1997 the Swedish National Register of Urinary Bladder Cancer (SNRUBC) was 
launched with a national coverage of over 90% from start that has now reached 97%, 
compared to the SCR (172, 173). The RCC Southeast is the responsible register holder. The 
register intends to include all incident cases of morphologically verified urinary bladder 
cancer according to the International Classification of Diseases for Oncology, 3rd revision 
code C67.0-C67.6 and C67.8-C67.9 in Swedish adults (age ≥18) (172). The original version 
consisted of a minimal set of variables (age, sex, date of diagnosis, tumor characteristics, 
primary treatment within 3 months from diagnosis), but have now expanded to include 
several forms covering detailed clinical diagnostic information (tumor location, size, grade, 
TNM stage, dates to estimate waiting times, and performed diagnostic investigations), pre- 
and postoperative data including surgical details in those undergoing radical cystectomy, and 
a 5-year follow up of non-muscle invasive tumors. Several quality indicators have been 
identified and these are continuously evaluated to compare and encourage regional and 
temporal improvements in the management of urinary bladder cancer.  
Figure 2. The constituting Swedish registers forming the Bladder Cancer DataBase Sweden (BladderBaSe). 
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With the aim of performing epidemiological research to study bladder cancer, SNRUBC data 
from year of diagnosis 1997-2014 was linked to several national healthcare and demographic 
registers to construct the Bladder Cancer DataBase Sweden (BladderBaSe) in 2015 (Figure 2) 
(172). 3.1.3 Auxiliary national registers provides a detailed description of the included 
registers. 
3.1.3 Auxiliary national registers 
If not otherwise stated, the Swedish National Board of Health and Welfare maintains the 
listed and described national health registers.  
The Swedish National Patient Register (NPR) started as the Hospital Discharge Register 
already in 1964, but due to different recording practices and a staggered introduction, it did 
not reach complete national coverage of all in-patient care until 1987. In addition to 
demographic information similar to that in the SCR, the NPR contains hospital administrative 
data including dates of hospital admission and discharge as well as main and secondary 
discharge diagnoses and major interventions according to ICD-7 (year 1964-1967),  ICD-8 
(year 1968-1986), ICD-9 (year 1987-1996), and ICD-10 (year 1997-). The coverage and 
validity of the NPR is high with more than 99% of all somatic and psychiatric hospital 
discharges reported and roughly 90% of the diagnoses being valid (165, 174). Surgical 
daycare procedures and specialized outpatient visits (not primary care) were added to the 
register from the years 1997 and 2001, respectively. The national coverage of outpatient care 
is only around 80%, mainly due to under-reporting from private caregivers (174).  
The Swedish Cause of Death Register was established in 1961, but death data for year 1952-
1960 has been compiled retrospectively from medical records (175). The register contains 
date and underlying and contributing causes of death, and is used for official statistics and 
medical research (175). The proportion of missing death certificates is close to 0% (165, 
175). Within three weeks from death, the death certificate including a version of the 
International Form of Medical Certificate of Cause of Death, has to be submitted by the 
responsible physician to the National Board of Health and Welfare. This form is used to 
identify underlying and contributing causes of death according to the rules from the ICD 
version currently in practice (175). Approximately 2.7% of all deaths lack a specific 
underlying cause of death but the proportion is higher in elderly with multiple chronic 
conditions (175). The quality of the register is dependent on the quality of the submitted 
death certificates. A 77% agreement with the expected cause of death from medical case 
summaries have been reported in Sweden (176). The agreement was however found to be 
higher in case of underlying malignant disease (176).  
The Swedish Prescribed Drug Register was launched in 2005 and is one of the most recent 
nationwide healthcare registers (177). The register contains detailed information, including; 
substance, brand name, formulation, package, amount, and dosage, on prescribed and 
dispensed drugs in the Swedish population. Data is raised by the state-owned National 
Corporation of Swedish Pharmacies and transferred to the National Board of Health and 
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Welfare annually (177). Drugs are classified according to the Anatomical Therapeutic 
Chemical (ATC) classification system (178).  
Statistics Sweden administers the Total Population Register as well as the Longitudinal 
Database for Health Insurance and Labor Market studies (LISA) which handles information 
on marital status, country of birth, dates of immigration and emigration in addition to 
individual- and group-level data on socioeconomic factors such as education, employment, 
and income (165, 179). Statistics Sweden additionally provides open-access data on 
population counts and mortality by sex, age, and calendar year, to use as denominators when 
estimating approximations of cancer incidence and excess mortality in the population, see 
3.2.1 Relative survival (165).  
3.1.4 Data on body height 
The Swedish Passport Register was computerized in 1991 and includes body height (self-
reported or measured at time of application), sex, photo of passport holder, as well as 
administrative information including the NRN (180). Swedish citizens apply for a passport at 
the Swedish Police to facilitate international travel and for identification. Since 2005 an adult 
Swedish passport is valid for 5 years, but can also be renewed if lost or destroyed. 
The Swedish Conscription Register is held by the Swedish National Archives and includes 
data on all conscripted Swedes since 1967. Conscription and military service was mandatory 
by law for all Swedish men until mid-2010, with a very small (2-3%) dropout rate, mainly 
due to severe medical conditions. The register contains information on height, weight, 
physical examination, together with cognitive tests at time of recruitment (usually at age 17-
20).  
The Medical Birth Register was established in 1973 for congenital malformation surveillance 
purposes. The register contains data collected at antenatal care visits including; maternal 
height, weight, concurrent disease, and smoking habits, as well as delivery including; birth 
weight, gestational age, and Apgar score. All mothers attending the public prenatal system 
are included in the register contributing to a coverage of approximately 97.0-99.5% of all 
births in Sweden (165).  
The height dataset in study IV contains attained adult body height in 6,156,659 individuals. 
This database was created linking individual-level data on height from the passport register, 
the conscription register, and the medical birth register, using the NRN (Figure 3). In case of 
multiple, dissimilar height registrations within individual, the most frequent, tallest height 
was used and measured heights (conscription and medical birth registers) were prioritized 
rather than self-reported ditto (passport register).  
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Figure 3. The Swedish registers contributing with information on adult height. 
 
 
3.2 METHODOLOGY 
The final decision of which statistical methods to apply is not always straight-forward. In this 
doctoral project, methodology was partly defined from start (relative survival in study I). In 
study II and III multiple steps, taking both results from previously performed studies as well 
as findings in our own data into account, preceded the final decisions. Causal inference is an 
expanding area of focus in medical research. In study IV, this resulted in the application of a 
contemporary, not previously applied, method to perform mediation analysis of a time-to-
event outcome (181). This section aims to motivate and give a more detailed background and 
description to the underlying methodology than can be fitted into a scientific publication. For 
details on data management, definitions, groupings of variables, and exact model 
composition, please see the attached publications and manuscripts, studies I-IV. 
3.2.1 Relative survival 
3.2.1.1 Motivation 
Net mortality is the preferred measure when comparing cancer mortality in two populations 
with different non-cancer mortality, such as between countries, time periods, or men and 
women. Net survival is a hypothetical measure in a scenario where the disease of interest is 
the only possible cause of death. It can be estimated either in a cause-specific (using 
information on underlying cause of death) or in a relative survival setting (182). The relative 
survival in a cancer patient cohort is defined as the ratio between the observed all-cause 
survival in the cancer group and the expected survival from a comparable cancer-free group. 
The expected survival is commonly retrieved from publicly available population life tables, 
stratified on age, sex, and calendar year. Register-based cancer studies often present relative 
survival, circumventing the issue with non-reliability and/or non-availability of death 
certificates (44). Information from death certificates are often inaccurate and a brief 
background to the death certificate procedure in Sweden is described in 3.1.3 Auxiliary 
national registers. Another advantage of relative survival is that the approach captures both 
Height dataset 
birth cohort: 
1900-1991 
(n=6,156,659) 
Passport Register  
issue year: 1991-2012 
(n=4,432,242)
Conscription Register 
year: 1960-2010 
(n=1,298,083)
Medical Birth Register 
birth year: 1980-2012 
(n=426,334)
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the direct and indirect effects of cancer on mortality (44). For example, lethal infections and 
cardiovascular deaths can occur as a result of malignant disease or treatment thereof, but also 
independently of cancer, making the true underlying cause of death in the individual hard to 
assess (183). Cancer mortality has consequently been shown to be over-estimated in older, 
comorbid populations when using a cause-specific approach (44, 183). 
When applying a relative survival framework, it is a delicate task to assess how well the 
survival expected in the absence of the disease under study, is captured in relation to the 
patient group (44). As mentioned above, the expected survival is usually estimated using 
national life tables connoting the fundamental assumption that if the patient group did not 
have the disease of interest, they would have the same survival as the general population (44). 
This can be questioned, particularly in smoking-related cancers. Since smokers have a shorter 
life expectancy compared to the general population due to a higher comorbidity burden, a 
potential concern is that the cancer mortality in this group is over-estimated. This issue has 
however been shown to have a small impact on relative survival estimates, at least in 
malignancies with poor survival like lung cancer (184). 
3.2.1.2 Application (study I) 
In study I, we applied a relative survival framework to estimate cancer survival in men and 
women with the overarching aim to illustrate and quantify sex differences in cancer patient 
mortality (185). The 5-year relative survival ratio (RSR) was estimated as the observed 
survival in the cancer patient group 5 years from diagnosis divided by the corresponding 
observed survival in the Swedish population, using a cohort approach. The expected 
mortality, matched by age, sex, and calendar year, was estimated using the Ederer II method 
(186). Population-weighted survival estimates may be misleading since the age distribution of 
the cancer patients varies over time and age at diagnosis affects prognosis. We consequently 
age-standardized the RSR estimates according to the International Cancer Survival Standards 
using the age distribution proposed for malignancies increasing with age in broad classes 
(187). 
The mortality analogue of relative survival, excess mortality, was estimated as the absolute 
difference between the all-cause mortality in the cancer cohort and the all-cause mortality in 
the general population (44, 186). To compare excess mortality between men and women, 
male-to-female excess mortality ratios (EMRs) with 95% confidence intervals (CIs) were 
estimated using a Poisson regression model adjusted for age and year of diagnosis, allowing 
for the effect of sex to vary over follow-up time.  
All statistical analyses were performed using Stata Intercooled version 14.0 (StataCorp LP), 
the Stata command “strs” was applied when estimating relative survival (188).  
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3.2.2 Flexible parametric models 
3.2.2.1 Motivation 
A popular approach when contrasting the survival outcome in two groups, exposed versus 
unexposed, is to plot Kaplan-Meier survival proportions over follow-up together with one 
summary measure, the hazard ratio, estimated using a Cox proportional hazards regression 
model. This is in many cases adequate and Kaplan-Meier curves are, in the absence of 
competing risks, intuitive to interpret. In a randomized clinical trial, the exposure is the only 
determinant supposed to differ between the two groups and any difference in survival is 
interpreted as an effect of the exposure. In observational studies, like those presented in this 
thesis, we expect confounding of the exposure-outcome relationship, meaning that Kaplan-
Meier curves do not represent and visualize the direct exposure effect.  
Although Cox models provide a solution to adjusting for potential confounders, only one 
relative effect measure is estimated, namely the hazard ratio. The hazard ratio does not have a 
natural, authentic interpretation and ignores baseline risk, absolute differences (clinical 
relevance), and diversity among study subjects. Moreover the proportional hazards 
assumption, usually made in Cox models, implies that the ratio of the hazards (mortality 
rates) is constant over follow-up time. It is implausible to believe that the natural history of 
disease and underlying causes of clinical events constantly behave proportionally.  
An alternative to the Cox model is the flexible parametric model suggested by Royston and 
Parmar (189). This model captures the different underlying hazard shapes without making 
strong assumptions about the functional forms. Furthermore, flexible parametric models yield 
absolute effect measures. Modeling is usually done on the cumulative hazard scale. The 
baseline hazard is modeled using natural cubic splines; mathematical functions defined by 
piecewise cubic polynomials with additional constraints, to produce smooth predictions. The 
model can estimate hazard ratios under proportional hazards, yielding close to identical 
estimates compared to the Cox model. But the proportional hazards assumption can also 
easily be relaxed by including interaction terms between the covariates and time scale in the 
model. With further extensions, the flexible parametric model readily predicts and visualizes 
smoothed hazard functions and hazard ratios over different time scales (189, 190).  
User-written commands have been developed in Stata and are continuously updated with 
improved functionality and computational efficiency (189, 190). Flexible parametric models 
were, to a varying extent, applied in all of the included studies.  
3.2.2.2 Application (study II and III) 
In study II, non-small cell lung cancer (NSCLC) and study III, urothelial bladder cancer 
(UBC), we applied flexible parametric models to study sex differences in cause-specific 
mortality and survival (190-192).  
A reasonable starting point, in both studies II-III, was plotting the empirical survival 
proportions for men (unexposed) and women (exposed) over follow-up using the Kaplan-
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Meier method. Visual inspection of the graphs confirmed a male survival disadvantage in 
NSCLC and an advantage in UBC. In study III (UBC) we additionally plotted the smoothed 
empirical mortality rates, i.e., number of deaths/person-years, over follow-up for men and 
women. This revealed that the majority of the excess deaths due to bladder cancer occurred 
within two years from diagnosis. To provide a non-parametric, absolute measure of cancer-
specific mortality, we calculated the number and percentage of cancer-specific deaths within 
5 years from NSCLC diagnosis and two years from UBC diagnosis, in men and women 
respectively. 
With the purpose to further outline and quantify sex differences in cause-specific mortality, 
we subsequently applied flexible parametric models (190). Firstly, we evaluated the 
proportional hazards assumption for sex by estimating and plotting the female-to-male 
mortality rate ratio over follow-up time from a flexible parametric model with non-
proportional hazards. The baseline hazard function was modelled with a restricted cubic 
spline with 5 degrees of freedom (df) and the time-dependent effect of sex included 3 df. 
Examining the graphs, we concluded that the proportionality assumption did not hold since 
this would have resulted in a flat line, see Figure 4, exemplifying the female-to-male hazard 
ratio over follow-up in NSCLC.  
Figure 4. Female-to-male hazard rate ratio (HR) including 95% confidence interval (shaded area) over follow-up, 
standardized over age, calendar year, education, marital status, birth country, health care region, ECOG performance status, 
smoking history, Elixhauser comorbidities, TNM stage, and primary tumor location.  
 
Since the purpose was to investigate the extent to which the measured covariates could 
explain sex differences in cancer mortality we continued by estimating the female-to-male 
hazard ratio, again employing flexible parametric models (190). To enable comparisons with 
previously reported findings, we started by fitting a univariate model, thereafter adding one 
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covariate at a time, evaluating the effect on the main outcome, the cancer-specific mortality 
ratio. As an additional sensitivity analysis to explore any potential effect modification, we 
tested models allowing for interactions between sex and a number of covariates. In the end, 
we presented two models in study II (NSCLC) and three models in study III (UBC), based on 
ours and previously reported findings (191, 192).  
To verify the results in study II (NSCLC), we additionally applied a Cox proportional hazards 
model to estimate female-to-male cancer-specific mortality ratios, including the same 
covariates as in the fully adjusted flexible parametric survival model. As expected, we found 
the HR estimates to be almost identical to the output from the flexible parametric models 
assuming the effect of sex to be proportional over follow-up time (191). 
To further outline and provide a more intuitive quantitative measure of sex differences in 
survival than hazard ratios, we plotted standardized survival proportions with 95% CIs, in 
men and women, over time since diagnosis. These were estimated from flexible parametric 
models, but with a slightly different approach in study II and III, respectively. In study II 
(NSCLC) we wanted to visualize the survival under two counterfactuals where the only thing 
differing between the two scenarios was patient sex (i.e., the remaining covariate distribution 
was kept identical in the two groups). We consequently predicted one survival curve for each 
individual and averaged over all included covariates. This allowed us to create two 
standardized curves where the only difference between the curves was that in one everyone 
was exposed (female sex) and in the other everyone was unexposed (male sex). The baseline 
hazard function was fitted using restricted cubic splines with 5 df and the time-dependent 
effect of sex was modelled using 3 df. To contrast the survival in men and women, we 
estimated the absolute difference in standardized survival at 1, 3, and 5 years from diagnosis. 
In study III (UBC) we predicted the survival in women standardized to the observed covariate 
distribution in men. This is interpreted as the survival in women if women had the same age, 
comorbidity burden, stage, etcetera as men. The df for the restricted cubic splines in the 
baseline hazard functions and time-varying effect of sex, were the same as in study II. The 
survival proportion in women standardized to the male covariate pattern was added to the 
traditional Kaplan-Meier survival curves for men and women, to evaluate a potential shift. 
3.2.2.3 Modelling and goodness-of-fit (study I) 
See 3.2.1 Relative survival for a description of the background and advantages of applying a 
relative survival framework and definitions of the relative survival ratio (RSR) and excess 
mortality ratio (EMR).   
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Figure 5. Non-Hodgkin lymphoma (A) 5-year relative survival in men and women and (B) male-to-female excess mortality 
ratio (EMR), comparing yearly, empirical estimates (dots) with modelled predictions using restricted cubic splines with three 
degrees of freedom, including 95% confidence interval (CI, shaded area). 
 
Table 4. Applying the Akaike information criterion (AIC) to compare goodness-of-fit using 3 or 4 degrees of freedom (df), 
when estimating male-to-female excess mortality ratios by year of diagnosis. 
Anatomical tract Cancer site AIC (3 df) AIC (4 df) 
3 superior  
to 4 df 
Head-neck 
Lip 9204 9205 yes 
Tongue 14088 14090 yes 
Salivary glands 8608 8599 no 
Other oral cavity 16931 16923 no 
Pharynx 15016 15019 yes 
Tonsils 8679 8677 no 
Thyroid well-differentiated 10274 10277 yes 
Thyroid anaplastic 6456 6456 yes 
Upper digestive 
Esophagus adenocarcinoma 10846 10842 no 
Esophagus squamous cell 17991 17994 yes 
Stomach 49273 49271 no 
Liver primary 21190 21191 yes 
Biliary tract 29704 29701 no 
Pancreas 34827 34820 no 
Lower digestive 
Small intestine 18284 18279 no 
Colon 66670 66653 no 
Rectum 55113 55112 no 
Anus 10063 10066 yes 
Respiratory 
Nasal cavity/sinuses 8448 8452 yes 
Larynx 14902 14894 yes 
Lung 61421 61401 no 
Lung squamous cell carcinoma 17253 17254 yes 
Lung adenocarcinoma 23205 23207 yes 
Lung small cell carcinoma 14352 14356 yes 
Lung other non-small cell 17461 17465 yes 
Pleura mesothelioma 10047 10051 yes 
Urinary 
Urinary tract 46154 46153 no 
Kidney 41370 41373 yes 
Skin 
Skin melanoma 40172 40143 no 
Skin non-melanoma 32852 32846 no 
CNS 
Brain 30810 30814 yes 
Meninges 12987 12987 yes 
Hematological 
Non-Hodgkin lymphoma 48583 48576 no 
Chronic lymphocytic leukemia 16796 16799 yes 
Hodgkin lymphoma 14529 14532 yes 
Multiple myeloma 35525 35526 yes 
Acute lymphocytic leukemia 7109 7109 yes 
Acute myeloid leukemia 20944 20949 yes 
Chronic myeloid leukemia 8143 8143 yes 
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In study I we fitted age-standardized 5-year RSR for men and women together with age-
adjusted male-to-female EMR by calendar time. The EMRs were estimated using flexible 
parametric models with 3 df for the baseline cumulative hazard function (190). This final 
model was chosen after comparing goodness-of-fit using different degrees of freedom. We 
started by doing a visual, subjective, comparison, plotting yearly EMR point estimates and 
spline modelled estimates by calendar time, for all cancer sites, as exemplified with non-
Hodgkin lymphoma, panel B in Figure 5. As an additional sensitivity analysis we used the 
Akaike information criterion (AIC) comparing 3 and 4 df for the baseline cumulative hazard 
function in the flexible parametric models, verifying that 3 df proved objectively better model 
fit (lower AIC value) than 4, for a majority of sites (Table 4). 
3.2.2.4 A counterfactual approach (study IV) 
In study IV flexible parametric models were again applied. This time arising from the precise 
counterfactual definitions of total and indirect effects described below in 3.2.4 Causal 
inference on time-to-event outcomes. We plotted the cancer-free survival in men 𝑆1𝑀1(𝑡) and 
in women 𝑆0𝑀0(𝑡) using age as the time scale (190). To quantify and illustrate the effect of 
height on cancer-free survival, we predicted and plotted the counterfactual survival 
proportion in men if they had the same height distribution as women 𝑆1𝑀0(𝑡) and women if 
they had the same height distribution as men 𝑆0𝑀1(𝑡) using height-standardized flexible 
parametric models. The proportion of the excess cancer risk in men explained by height (PE) 
was estimated as the survival difference in men before and after height standardization 
divided by the total survival difference, at age 90: 
𝑃𝐸 =
𝑆1𝑀1(𝑡) − 𝑆1𝑀0(𝑡)
𝑆1𝑀1(𝑡) − 𝑆0𝑀0(𝑡)
 
 
We used Stata Intercooled (StataCorp LP) version 14.0 (study I) and 15.1 (studies II-IV) and 
the Stata commands “stpm2” and “stpm2_standsurv” when applying flexible parametric 
models (190). 
3.2.3 Measuring comorbidity 
3.2.3.1 Motivation 
As discussed previously in 1.3.2 Patient characteristics, comorbidity poses a major issue and 
needs to be meticulously handled when studying different aspects of cancer survival (51). 
The innate complexity of comorbidity in itself, potentially interacting with basically every 
aspect of cancer mortality, entails no, single, optimal management. Information on 
comorbidity in observational population-based studies usually consists of administrative data 
extracted from in-patient medical records and is a rough, underestimate of real-world 
probabilities. Even when details on current medical history and symptoms are readily 
available in the routine clinical setting, it is hard to fully appraise the influence of concurrent 
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disease on cancer outcome. Relying on aggregated diagnostic codes without information on 
duration and severity of disease makes this task close to impossible. As often, when no gold 
standard exists, many approaches to assess the comorbidity burden in cancer patients have 
been developed. The two most commonly used; the Charlson Comorbidity Index (CCI) and 
the Elixhauser approach, together with a handful of alternative concepts will be briefly 
discussed in this section (51, 193, 194). 
3.2.3.2 The Elixhauser approach (study II) 
The Elixhauser approach is based on clinical experience and literature in the area together 
with empirical testing using administrative data on 1,779,167 adult acute care hospital 
patients (51, 194). This way, 30 medical conditions with impact on short-term outcome were 
identified (51, 194) The original version requires large datasets since the included conditions 
are treated as distinct, binary (yes/no) variables, using the underlying impact of each 
condition on mortality in the cohort under study (51, 194). The Elixhauser components can 
also be summarized and used as a count and methods to estimate a weighted summary score 
have been developed (51, 195). The method has been applied in a number of settings 
studying different malignancies and there is evidence of a predictive validity in most cancer 
sites as well as cancer in general (51). In study II we used data on main and secondary 
diagnoses at hospital discharge from the National Patient Register and data on other 
malignancies from the Swedish Cancer Register, recorded 15 years-1 month before date of 
lung cancer diagnosis to identify the Elixhauser disease entities (167, 174, 194). The ICD 
revision 9 was used for conditions registered in 1987-1996 and 10 in 1997–2016. When 
comparing the Elixhauser to the Charlson Comorbidity Index (CCI) groupings (using the 
same time frame and ICD revision), we found that the proportion of patients with score 0 (no 
comorbidity) was smaller; 35-44% compared to 48-60%, using the Elixhauser approach, see 
Table 5 (191). Comorbidity burden in this elderly, smoking-prevalent cohort of lung cancer 
patients was most probably underestimated using both methods, but less so applying the 
Elixhauser approach. Moreover, we had enough data to avoid potentially misestimated, 
outdated weights and could instead make use of the impact of each comorbid condition on 
morbidity in our cohort, as specified in the original Elixhauser approach (194). 
3.2.3.3 The Charlson Comorbidity Index (study III) 
The Charlson Comorbidity Index (CCI) is one of the earliest described and the most cited 
classification systems to assess concurrent disease (51, 193). Empirical analyses were applied 
to identify 17 disease conditions with prognostic potential in 608 patients receiving medical 
in-patient care in year 1984 (193). The original data consisted of clinical notes, but algorithms 
have been developed to use administrative data and even patient questionnaires (51). As 
originally specified, CCI is a weighted index where the weights correspond to the rounded, 
adjusted relative risk for mortality within one year from inpatient stay for each medical 
condition. The maximum weight was set to 6 and conditions with a relative risk < 1.2 were 
excluded (193). The CCI does not include alcohol abuse, obesity, drug abuse, angina, 
osteoporosis, non-diabetes endocrine disorders, and tuberculosis, among other conditions. 
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The approach has been validated in a number of studies and the score has been re-weighted 
and reduced to include 12 conditions, to match progress in medical care (51, 196). Multiple 
studies in different settings and on separate malignancies have applied the CCI and/or 
different adaptions using the same disease categorization (51). In study III we did not have 
access to source data from the NPR to estimate and compare different approaches to assess 
comorbidity. Information on the CCI for each study subject, according to the original version, 
was delivered by the BladderBaSe holders (172). The proportion of patients with CCI 0 was 
found to be surprisingly high, 52-69%, in this elderly patient cohort with a high smoking 
prevalence. Moreover the CCI increased with calendar time indicating that a longer time-
window had been used in patients diagnosed in latter time periods. We concluded that the 
true comorbidity burden was definitely underestimated and that the underlying reasons are 
probably related to the method in itself and/or in combination with inaccurate data extraction 
and management (192). 
Table 5. Numbers (n) and proportions (%) of men and women diagnosed with lung squamous cell and adenocarcinoma, 
comparing different measures of comorbidity. 
    Squamous cell carcinoma   Adenocarcinoma 
  Men  Women p-
value 
 Men  Women p-
value     n %   n %   n %   n % 
Charlson Comorbidity Index                         
0  3115 47.5  1953 51.8   5652 52.4  7614 60.1  
1-2  2280 34.8  1248 33.1   3215 29.8  3336 26.3  
3+  1161 17.7  568 15.1 0.000  1928 17.9  1720 13.6 0.000 
Elixhauser approach               
0  2261 34.5  1386 36.8   4196 38.9  5557 43.9  
1-2  2628 40.1  1469 39.0   4171 38.6  4842 38.2  
3-4  1151 17.6  628 16.7   1703 15.8  1617 12.8  
5+  516 7.9  286 7.6 0.130  725 6.7  654 5.2 0.000 
Pharmaceutical groups1             
0-2  1658 35.0  862 29.9   3292 37.9  3891 37.3  
3-6  2106 44.4  1340 46.4   3817 43.9  4690 45.0  
7+  974 20.6  683 23.7 0.000  1578 18.2  1848 17.7 0.352 
Outpatient visits2               
0-1  3868 63.3  2207 61.5   6606 63.6  7767 63.6  
2-4  1429 23.4  863 24.1   2396 23.1  2821 23.1  
5+  818 13.4  518 14.4 0.184  1384 13.3  1632 13.4 0.997 
Inpatient visits               
0  5190 79.2  3024 80.2   8816 81.7  10640 84.0  
1  807 12.3  436 11.6   1164 10.8  1295 10.2  
2+   559 8.5   309 8.2 0.418   815 7.5   735 5.8 0.000 
1Year of diagnosis 2006-2016. 2Year of diagnosis 2003-2016. 
 
 
3.2.3.4 Alternative concepts (study II) 
Using pharmaceutical data to calculate medication-based indices poses an attractive 
alternative or supplement to traditional comorbidity indices since this method bypasses 
potentially inaccurate recording of diagnoses. Prescribed medications also captures diseases 
managed in out-patient clinics and to some extent reflects disease severity. The method will 
however only include conditions for which regular drugs are prescribed and is vulnerable to 
utilization and prescribing habits. No medication-based index to measure comorbidity in 
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cancer patients has been developed (51). Since LCBaSe contains linked data on prescribed 
and dispensed medications we attempted to make use of this information (177). We created 
counts of number of different classes of prescribed drugs, grouped according to the first three 
positions of the Anatomical Therapeutic Chemical (ATC) classification system, dispensed 6-
18 months before lung cancer diagnosis (Table 5). This yielded a straightforward 
approximation of number of medications of different conditions, as a rough additional proxy 
of concurrent comorbidity. The method does not consider dosage and pharmaceuticals 
indicating health awareness and/or resource consumption were assigned the same weight as 
drugs indicated for severe conditions.  
We additionally explored the number of out- and inpatient medical consultations in 
specialized (non-primary) health care 6-18 months prior to lung cancer diagnosis as a 
measure of comorbidity. The results were however hard to interpret since we did not have 
information on the cause for consultation, and visits due to pre-malign symptoms and 
investigations of these are doubtlessly included. Unlike the other explored comorbidity 
approaches, women and men had an equally high disease burden, measured as number of 
consultations (Table 5). We believe that this reflects a higher health care consumption rather 
than comorbidity burden in women, compared to men (191). 
3.2.4 Causal inference on time-to-event outcomes 
3.2.4.1 Motivation 
Methodology for causal mediation analysis in epidemiological research is a rapidly 
advancing research field (197). The purpose of mediation analysis is to quantify possible 
mechanisms, i.e., pathways, through which an exposures executes or mediates effect on the 
outcome under study (198). The total outcome effect is separated into indirect and direct 
effects, where the indirect effect works through the mediator(s) under study. A mediator is on 
the causal pathway between the exposure and the outcome. The ratio of the indirect effect and 
the total effect is the proportion mediated and a relative assessment of the pathway of interest 
(198).  
So far, most methods have been developed to disentangle indirect and direct effects on point 
estimates rather than time-to-event outcomes. We wanted to quantify to what extent the 
excess cancer risk in men is mediated by height, as a proxy of cumulative number of stem 
cell divisions. A newly developed methodology (study IV), the regression coefficient method 
was consequently applied to assess to what extent body height (mediator) explains the 
increased cancer risk (outcome) observed in men (exposure) (181).  
A causal interpretation of indirect and direct effects, irrespective of methodology, requires 
fairly strong assumptions regarding confounding (181, 197, 198). Exposure-outcome (applies 
to all observational studies), mediator-outcome, and exposure-mediator confounders can all 
be controlled for by including the covariates of interest in the regression models (197). A 
potential mediator-outcome confounder affected by the exposure is more problematic since 
this confounder in itself acts as a mediator, see Figure 6 (197-199).  
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Figure 6. Directed acyclic graph, DAG; A, exposure; Y, outcome; M, mediator; C, classic confounder; L, mediator-outcome 
confounder affected by the exposure. 
 
 
3.2.4.2 The regression coefficient method and application (study IV) 
In addition to the general confounder assumptions, conclusions from the regression 
coefficient method can only be made presuming that the exposure (male sex) and mediator 
(height), measured at baseline, remain unchanged during follow-up (181). Moreover, the 
mediator is assumed to fit a linear regression model and the outcome (time to cancer 
diagnosis) is supposed to be rare and follow a Cox proportional hazards regression model 
(181). 
Cancer-free survival (i.e., time-to-cancer) was computed from date of height measurement 
until date of site-specific cancer diagnosis and was censored at date of death, emigration, or 
end of follow-up (December 31, 2011), whichever occurred first. Birth year and educational 
level are both associated with height as well as cancer risk, see 1.4 Height and cancer risk, 
and were, if not otherwise stated, included in the outcome models.   
An established counterfactual approach to define total and indirect effects were applied (200-
202). The proportion of subjects remaining cancer-free at time 𝑡 was denoted 𝑆𝑎(𝑡) if the 
exposure was set to 𝑎 (1=male or 0=female) for everyone and the total effect was 
consequently defined as the difference in cancer-free survival in men and women:  
𝑆1(𝑡) − 𝑆0(𝑡) 
Furthermore the counterfactual equivalent, 𝑆𝑎𝑀𝑎∗ (𝑡), implied the proportion remaining 
cancer-free if the exposure was set to 𝑎 and the mediator (height), for each subject, was set to 
the value it would have had if the exposure simultaneously was set to 𝑎∗ (not necessarily 
equal to 𝑎). The indirect effect of male sex (the pathway mediated through height) was 
defined as the difference in cancer-free survival in men at actual (male) height and men at 
counterfactual (female) height, the only thing differing between these two populations being 
the height distribution:  
𝑆1𝑀1(𝑡) − 𝑆1𝑀0(𝑡) 
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The ratio of the indirect and total effect define the proportion explained by mediation (PE) 
(181, 197, 198, 202-204): 
𝑃𝐸 =
𝑆1𝑀1(𝑡) − 𝑆1𝑀0(𝑡)
𝑆1(𝑡) − 𝑆0(𝑡)
 
Under the previously described assumptions the proportion explained by mediation may be 
approximated as a function of the standard regression coefficients (181):  
𝑃𝐸 ≈
𝑒𝛾1(𝑒𝛽𝛾2 − 1)
𝑒𝛾1+𝛽𝛾2 − 1
 
The regression coefficient 𝛾1 measures the direct effect of the exposure on the outcome, if 
𝛾1 = 0, the proportion mediated is equal to 1, i.e., 100% of the exposure effect on outcome is 
executed through height. The regression coefficient 𝛽 measures the effect of the exposure on 
the mediator in the linear regression model and 𝛾2 the effect of the mediator on the outcome 
in the Cox regression model. If 𝛽 = 0 or 𝛾2 = 0 the proportion explained by mediation is 
equal to 0, i.e., none of the effect is mediated by height. (181). The PE was estimated by 
fitting the mediator and outcome models and then plugging the regression coefficient 
estimates into the expression. The delta method was used to construct a 95% confidence 
interval for the proportion mediated (181).  
A user-written function in R statistical software v.3.5.1 (R Foundation for Statistical 
Computing, Vienna, Austria) was used to estimate proportions explained by mediation (181). 
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 RESULTS 
The main results are all presented and discussed in detail in the attached studies I-IV. The 
purpose of this section is not to duplicate previously published and/or presented figures and 
tables. The aim is instead to add supporting material that did not fit into the final publications 
or manuscripts, but still illustrates how and why we ended up with the final results and 
conclusions. Some of the figures and tables have been included in the manuscripts including 
appendices and some have never been made public previously. 
Figure 7. Adjusted male-to-female incidence rate ratios (y-axis) and excess mortality ratios (x-axis) for all included cancer 
sites. Both axes are plotted on a logarithmic scale with base 2.  
 
ALL, Acute lymphoblastic leukemia; AML, Acute myeloid leukemia; CLL, Chronic lymphocytic leukemia; CML, Chronic 
myeloid leukemia; NHL, Non-Hodgkin lymphoma; AC, Adenocarcinoma, NSCL, Lung other non-small cell; SCC, Squamous 
cell carcinoma. 
4.1 STUDY I 
Figure 7 from study I provides a comprehensive overview of our main findings and is based 
on 872,397 cancer cases diagnosed in Sweden in 1970-2014 and at age 15-84 (185). Figure 7 
illustrates the male-to-female incidence rate ratio (IRR) together with the male-to-female 
excess mortality rate ratio (EMR) for all included non-sex specific cancer sites. Both 
estimates are adjusted for age and year of diagnosis. An IRR > 1 indicates higher cancer risk 
in men and an EMR > 1 poorer cancer survival in men. It is apparent that a majority of sites 
are aggregated in the upper right corner, being both more common and deadlier in men. 
Figure 7 is however constructed from aggregated data, incidence is based on cases diagnosed 
in year 1970-2014 and mortality on those diagnosed in 1995-2014. Consistency across 
calendar year and age at diagnosis is relevant to draw conclusions and generate hypotheses on 
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underlying drivers. Furthermore, incidence and relative survival in men and women over 
calendar time is interesting from a public health perspective to evaluate the effect of 
preventive work and advances in cancer care. We therefore decided to plot the sex-specific 
incidence rates (IRs) together with the male-to-female IRRs by year and age at diagnosis as 
well as the 5-year relative survival ratios (RSRs) together with the male-to-female EMRs by 
year of diagnosis for all cancer sites, please see Figure 8, Figure 9, and Figure 10, 
respectively. Estimates plotted over calendar time were adjusted for age and estimates by age 
were adjusted for calendar time.  
The incidence of most cancer sites increase over calendar time in both sexes while the excess 
cancer risk in men is more or less stable (Figure 8, page 34). The incidence of malignancies 
associated with smoking and/or alcohol, i.e., respiratory and head and neck tumors 
respectively, are decreasing slightly in both sexes. The slope is however steeper in men, 
resulting in a male-to-female IRR approaching, but not reaching 1. Pulmonary 
adenocarcinoma and small-cell lung cancer are the only exceptions and these tumors are 
nowadays more common in women than men (IRR < 1). Urothelial carcinoma is strongly 
associated with smoking, but incidence is not decreasing and moreover remains 3-4 times 
more common in men across the whole study period. Malignant melanoma incidence is the 
fastest increasing malignancy in both sexes and was more common in women in 1970’s but is 
thereafter consistently 10% more common in men. 
A majority of cancer sites increase with age in both sexes (Figure 9, page 37). The increase is 
more pronounced in men and the IRRs increase over age and peak around age 65-75. Some 
sites are more common in women up to age 40-50; salivary, colon, lung adenocarcinoma, 
small cell lung, other non-small cell lung, and malignant melanoma, suggesting different 
biological mechanisms in men and women. Biliary cancer is more common in men up to age 
40, but is thereafter surpassed by women. The remaining female predominated sites; anus, 
meninges, and thyroid, are consistently more common in women across age. 
Figure 10, page 40 shows 5-year RSR in men and women together with the male-to-female 
EMR by year of diagnosis. Survival has improved over calendar time for most malignancies 
and in both sexes. The female survival disadvantage is still more or less noticeable across the 
whole study period. The pattern is however far from as consistent as when studying 
incidence. For some sites; tongue, pharynx, gastric, pancreas, small intestine, colon, rectum, 
kidney, brain, multiple myeloma, ALL, and AML, survival differences have evened out over 
the last 5-10 years, indicating temporal changes in patient behavior and/or clinical 
management. Interestingly the largest survival difference is seen in sites that are both more 
common in women and have a very good prognosis (5-year relative survival > 80%), i.e., 
well-differentiated thyroid, meninges, salivary, melanoma, skin non-melanoma, NHL, CLL, 
and Hodgkin lymphoma. Perhaps indicating that pre-malign and/or earlier stage tumors are 
more frequently diagnosed in women. Biliary cancer stands out as exception and is both more 
common and deadlier in women, but also implies a very poor prognosis (5-year relative 
survival < 10%). 
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Figure 8. Age-adjusted male-to-female incidence rate ratio (IRR) and age-standardized incidence rate (IR) per 100,000 
person-years in men and women, by calendar year.
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Figure 9. Male-to-female incidence rate ratio (IRR) adjusted for year of diagnosis and incidence rate (IR) per 100,000 
person-years in men and women by age at diagnosis.
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Figure 10. Age-adjusted male-to-female excess mortality ratio (EMR) and age-standardized 5-year relative survival ratio 
(RSR) for men and women, by calendar year.
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From a public health perspective, it is appealing to quantify the impact of the excess cancer 
risk in men in the population. With this in mind we calculated the population attributable risk 
percent (PAR%), which is defined as the proportion  of incident cancers in the total 
population that can be attributed to sex differences in cancer risk (Table 6). The PAR% 
estimates ranged from negative values for cancer sites that are more common in women 
(biliary, anal, meningeal, thyroid) through 2% (lung adenocarcinoma) to 77% (laryngeal).  
Table 6. Proportion of cases attributed to male sex, i.e., population attributable risk percent (PAR%) with 95% confidence 
interval (CI). 
Anatomical tract Cancer site PAR% (95% CI) 
Head and neck 
Lip 61 (60-63) 
Tongue 28 (26-31) 
Salivary glands 9 (6-12) 
Other oral cavity 26 (23-28) 
Pharyngeal 51 (49-54) 
Tonsillar 46 (44-49) 
Upper digestive tract 
Esophagus adenocarcinoma 70 (68-72) 
Esophagus squamous cell carcinoma 44 (42-46) 
Gastric 34 (33-34) 
Liver primary 39 (37-41) 
Biliary tract -20 (-21--18) 
Pancreatic 11 (10-12) 
Lower digestive tract 
Small intestine 16 (14-18) 
Colon 7 (7-8) 
Rectal 25 (25-26) 
Anal -32 (-34--29) 
Respiratory organs 
Nasal cavity/sinuses 31 (28-35) 
Laryngeal 77 (76-79) 
Lung (all) 33 (32-33) 
Lung squamous cell carcinoma 41 (40-43) 
Lung adenocarcinoma 2 (1-4) 
Lung small cell carcinoma 13 (11-15) 
Lung other non-small cell 17 (15-18) 
Pleura mesothelioma 71 (69-73) 
Urinary 
Urothelial 55 (55-56) 
Renal 26 (25-27) 
Skin, central nervous system, 
thyroid 
Skin melanoma 3 (2-4) 
Skin non-melanoma 31 (31-32) 
Brain 21 (19-22) 
Meningeal -36 (-37--34) 
Thyroid well-differentiated -44 (-46--43) 
Thyroid anaplastic -18 (-22--14) 
Hematological malignancies 
Non-Hodgkin lymphoma 19 (19-20) 
Chronic lymphocytic leukemia 32 (31-34) 
Hodgkin lymphoma 16 (14-18) 
Multiple myeloma 20 (18-21) 
Acute lymphocytic leukemia 16 (12-21) 
Acute myeloid leukemia 10 (8-12) 
Chronic myeloid leukemia 18 (15-22) 
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4.2 STUDY II 
Study II aimed to explore potential factors driving the observed male survival disadvantage in 
non-small cell lung cancer, see 1.3.5 Non-small cell lung cancer, for a detailed introduction 
and background. Since pulmonary squamous cell carcinoma and adenocarcinoma are 
considered different disease entities with different epidemiology, clinical management, and 
prognosis, all analysis were stratified on cell type.  
We identified 33,790 cases of lung squamous cell carcinoma (n = 10,325) and 
adenocarcinoma (n = 23,465) diagnosed in Sweden in 2002-2016, at age ≥ 20 (see 3.1.2.1 
The National Lung Cancer Register and the Lung Cancer DataBase Sweden). Tables 1 and 2 
in study II provide an overview of sex differences in clinicopathological and socioeconomic 
factors, and treatment intensity, respectively (191). Men with NSCLC were older, less 
educated, and presented with poorer performance status and at a more advanced stage, upon 
diagnosis. Women with lung adenocarcinoma additionally presented with less comorbidity 
and were more often never-smokers. No, or minor sex differences, were found comparing 
treatment intensity in models adjusted for age and calendar time nor fully-adjusted. Our main 
finding, presented as adjusted lung cancer-specific hazard ratios and standardized survival 
curves, study II, table 3 and figure 2, respectively, concluded that men with NSCLC have a 
consistently poorer prognosis compared to women which was most pronounced in lung 
adenocarcinoma, and that cannot be explained by a range of prognostic factors (191). 
To fully explore if and how clinical management differs in men and women, we assessed 
investigational intensity (Table 7). We found no or very minor sex differences regarding 
clinical management of lung squamous cell carcinoma. In lung adenocarcinoma, 
thoracentesis was more often performed in men and positron emission tomography (PET) 
scans more frequently in women, conceivably reflecting different symptomatology and 
disease spread in men and women. In lung adenocarcinoma stage IIIB-IV, year of diagnosis 
2010-2016, EGFR testing was slightly more common in women. 
We additionally compared different waiting times in men and women diagnosed with lung 
squamous cell carcinoma and adenocarcinoma by plotting the cumulative proportion of 
patients by days from referral-to-diagnosis, diagnosis-to-treatment, and referral-to-treatment 
(Figure 11). No sex differences was obvious at visual inspection of the graphs. It was 
however striking that only 36-37% of NSCLC patients received a final treatment decision 
and/or initiated treatment within 28 days from referral (Table 7), a strong recommendation 
according to Swedish guidelines (79). 
A recently discovered favorable prognostic factor, as well as predictive of response to 
tyrosine kinase inhibitor therapy, in lung adenocarcinoma is activating EGFR mutations. 
EGFR positive tumors have also been shown to be more common in women compared to 
men. EGFR status is included in the NLCR from year 2010 and onwards. We performed a 
subgroup analysis of lung cancer specific mortality in patients diagnosed in 2010-2016 and 
tested for EGFR, adding a third model additionally adjusted for EGFR status (Table 8). The 
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female-to-male hazard ratios remained close to identical after adjusting for EGFR status in all 
stage groups and consequently EGFR status fails to explain the superior survival in women 
with lung adenocarcinoma.  
As a sensitivity analysis we explored models including an interaction term between sex and 
subset of variables, i.e., the effect of sex was allowed to vary over different covariate 
categories (Table 9). The presented p-value compares model fit with and without interaction, 
a p-value < 0.05 indicates that the latter model is superior. With the exception of smoking 
history in advanced stage lung adenocarcinoma, we did not find any evidence of a consistent 
trend together with significantly better model fit, when allowing for interaction. The female 
survival advantage was more pronounced in non-smokers (never or former) compared to 
smokers. The interaction between sex and birth country was based on very few non-
Scandinavian study participants and considered to be a random finding. 
Table 7. Numbers (n), percentages (%) of men and women diagnosed with non-small cell lung cancer and female-to male 
odds ratios (ORs) with 95% confidence intervals (CIs), undergoing diagnostic procedures, by histological subtype. 
  Squamous cell carcinoma 
 Men 
 Women 
n % OR (95% CI)  n % OR (95% CI)¹ aOR (95% CI)² 
Bronchoscopy 5413 82.6 1.00 (ref.)  3011 79.9 0.84 [0.76,0.94] 0.86 [0.76,0.96] 
CT thorax 6398 97.6 1.00 (ref.)  3676 97.5 0.97 [0.73,1.28] 0.89 [0.66,1.22] 
US/CT abdomen 5813 88.7 1.00 (ref.)  3317 88.0 0.95 [0.84,1.08] 0.97 [0.84,1.11] 
Thoracentesis 421 6.4 1.00 (ref.)  205 5.4 0.84 [0.71,1.00] 0.83 [0.68,1.00] 
Transthoracic biopsy 1459 22.3 1.00 (ref.)  1075 28.5 1.37 [1.25,1.51] 1.32 [1.19,1.47] 
CT/MRI brain3 1021 23.6 1.00 (ref.)  607 22.9 0.93 [0.83,1.05] 0.94 [0.82,1.07] 
PET scan3 1978 45.7 1.00 (ref.)  1305 49.2 1.10 [0.99,1.22] 1.07 [0.94,1.22] 
Multidisciplinary case 
conference 
4207 64.2 1.00 (ref.)  2506 66.5 1.03 [0.94,1.13] 1.00 [0.90,1.12] 
Treatment-on-time4 2375 36.2 1.00 (ref.)   1331 35.3 0.98 [0.90,1.07] 1.02 [0.92,1.12] 
 Adenocarcinoma 
 Men 
 Women 
n % OR (95% CI)  n % OR (95% CI)¹ aOR (95% CI)² 
Bronchoscopy 7487 69.4 1.00 (ref.)  8886 70.1 1.03 [0.97,1.09] 1.01 [0.95,1.08] 
CT thorax 10531 97.6 1.00 (ref.)  12343 97.4 0.84 [0.71,1.00] 0.82 [0.67,0.99] 
US/CT abdomen 9590 88.8 1.00 (ref.)  11341 89.5 1.06 [0.97,1.15] 1.07 [0.98,1.18] 
Thoracentesis 1967 18.2 1.00 (ref.)  1903 15.0 0.82 [0.76,0.88] 0.83 [0.76,0.90] 
Transthoracic biopsy 3191 29.6 1.00 (ref.)  3722 29.4 0.99 [0.93,1.05] 0.96 [0.90,1.02] 
CT/MRI brain3 2041 25.2 1.00 (ref.)  2424 24.8 0.95 [0.89,1.02] 1.01 [0.94,1.10] 
PET scan3 3367 41.6 1.00 (ref.)  4460 45.6 1.15 [1.09,1.23] 1.04 [0.95,1.12] 
Multidisciplinary case 
conference 
6869 63.6 1.00 (ref.)  8455 66.7 1.08 [1.02,1.14] 1.00 [0.93,1.07] 
Treatment-on-time4 4034 37.4 1.00 (ref.)  4630 36.5 0.94 [0.89,0.99] 0.98 [0.92,1.04] 
EGFR testing5 3263 53.4 1.00 (ref.)   4235 57.3 1.11 [1.03,1.19] 1.10 [1.01,1.20] 
¹Adjusted for age and calendar year of diagnosis. ²Additionally adjusted for level of education, marital status, country of birth, 
health care region, ECOG performance status, smoking history, Elixhauser comorbidity categories, TNM stage, and primary tumor 
location. 3Year of diagnosis 2007-2016. 4Treatment within 28 days from referral. 5Stage IIIB-IV, year of diagnosis 2010-2016. 
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Figure 11. Proportion of non-small cell lung cancer patients waiting (days) from referral-to-diagnosis, diagnosis-to-
treatment, and referral-to treatment (with dashed vertical line recommended waiting time < 28 days), by cell type. 
 
 
Table 8. Subgroup analysis of lung adenocarcinoma diagnosed in 2010-2016 and tested for EGFR, by stage group. Numbers 
(n), percentages (%) of lung cancer deaths and female-to-male hazard ratios (HRs) with 95% confidence intervals (CIs). 
  n % HR (95% CI)1 HR (95% CI)2 HR (95% CI)3 
Stage IA-IIB  
Men 149 22.6 1.00 1.00 1.00 
Women 157 16.8 0.64 [0.51,0.80] 0.65 [0.50,0.85] 0.65 [0.50,0.85] 
Stage IIIA  
Men 138 49.3 1.00 1.00 1.00 
Women 177 46.0 0.88 [0.70,1.10] 0.91 [0.69,1.18] 0.93 [0.71,1.21] 
Stage IIIB-IV  
Men 1665 73.0 1.00 1.00 1.00 
Women 2012 70.0 0.85 [0.79,0.90] 0.88 [0.82,0.94] 0.90 [0.84,0.97] 
1Adjusted for age and calendar year of diagnosis. 2Additionally adjusted for level of education, marital status, country 
of birth, health care region, ECOG performance status, smoking history, Elixhauser comorbidity categories, TNM 
stage, and primary tumor location. 3Additionally adjusted for EGFR status. 
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Table 9. Adjusted* female-to-male hazard ratios (HRs) by non-small cell lung cancer subtype and stage, exploring 
interaction between female sex and selected covariates and model fit (p-value) compared to the original model. 
  Squamous cell carcinoma   Adenocarcinoma 
 
stage IA-IIB Stage IIIA Stage IIIB-IV 
 
stage IA-IIB stage IIIA stage IIIB-IV 
  
 HR p-value HR p-value HR p-value  HR p-value HR p-value HR p-value 
Age               
20-59 0.75   1.45  0.99   0.71  0.87  0.96  
60-69 0.90   0.91  0.78   0.69  0.85  0.78  
70-79 0.78   0.93  0.88   0.72  0.73  0.80  
80-89 0.73   1.32  0.89   0.76  0.73  0.97  
90+ 1.93 0.455 1.88 0.150 1.70 0.057  1.26 0.876 0.00 0.676 0.62 0.000 
Year of diagnosis            
2002-2006 0.85  0.94  0.82   0.75  0.68  0.85  
2007-2011 0.81   1.09  0.91   0.72  0.73  0.82  
2012-2016 0.73 0.646 1.07 0.648 0.86 0.349  0.69 0.791 0.93 0.114 0.85 0.701 
Education             
low 0.79  1.29  0.87   0.73  0.80  0.87  
middle 0.87   0.93  0.82   0.68  0.78  0.82  
high 0.67   0.67  0.97   0.78  0.80  0.82  
missing 0.78 0.706 0.63 0.010 0.90 0.409  0.80 0.832 0.71 0.994 0.74 0.241 
Origin              
Scandinavian 0.78   1.01  0.86   0.73  0.80  0.84  
European 1.24   1.15  0.99   0.77  0.63  0.76  
Non-
European 
3.24 0.017 2.41  0.56   0.14  0.77 0.690 0.87  
missing -  1.76 0.456 0.98 0.323  0.61 0.058 -  1.02 0.576 
Performance status            
0 0.67   0.86  0.80   0.71  0.81  0.86  
1 0.81   1.06  0.88   0.70  0.81  0.84  
2 0.79   0.99  0.94   0.92  0.79  0.85  
3 1.14   1.12  0.89   0.61  0.49  0.83  
4 1.02   2.53  0.51   0.23  1.66  0.86  
missing 0.72 0.418 1.27 0.513 0.93 0.001  0.49 0.106 0.42 0.264 0.68 0.303 
Smoking history             
Smoker 0.79   1.18  0.85   0.75  0.96  0.79  
Former 
smoker 
0.80   0.89  0.87   0.69  0.65  0.84  
Never 
smoker 
0.62   0.98  0.90   0.72  0.79  0.95  
missing 1.88 0.179 1.20 0.263 1.07 0.753  0.66 0.879 1.11 0.031 0.93 0.010 
Elixhauser comorbidities           
0 0.77   0.98  0.87   0.86  0.81  0.84  
1-2 0.82   1.01  0.86   0.66  0.77  0.83  
2-3 0.85   0.94  0.86   0.75  0.71  0.90  
5+ 0.80 0.962 1.73 0.167 0.85 0.987   0.55 0.057 1.02 0.658 0.84 0.563 
*age, calendar year, educational level, marital status, birth country, health care region, ECOG performance status, smoking 
history, Elixhauser comorbidity groups, TNM stage, and primary tumor location. 
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4.3 STUDY III  
Urinary bladder cancer is one of few malignancies where women have a consistently poorer 
prognosis, see 1.3.6 Urinary bladder cancer for a detailed background. With the use of a 
comprehensive research database, BladderBaSe, we identified 36,344 Swedish men and 
women diagnosed with urothelial bladder cancer (UBC), at age 18-89, in year 1997-2014 (see 
3.1.2.2 The Swedish National Register of Urinary Bladder Cancer and the Bladder Cancer 
DataBase Sweden). Due to distinct clinical management, treatment and prognosis, we 
stratified all analyses into three mutually exclusive stage groups at diagnosis; non-muscle 
invasive (NMIBC: T0/Tis/Ta/T1, any N, M0), muscle invasive (MIBC: T2/T3/T4, any N, 
M0), and primarily metastasized (M1) UBC, see 1.3.6 Urinary bladder cancer.  
Main findings are presented in detail in the attached manuscript, study III (192). In summary 
we found the female survival disadvantage to be limited to MIBC, only noticeable within the 
first two years from diagnosis, and robust for adjustments for a range of prognostic factors. 
With the exception of an adverse stage distribution in women, we did not find any evidence 
of an inferior management of women with UBC, compared to men (192).  
Figure 12. Proportion of urothelial bladder cancer patients waiting (days) from referral-to-diagnosis (with dashed vertical 
line recommended waiting time < 22 days), by stage group. 
 
In addition to diagnostic and treatment intensity (table 2, study III), we investigated time from 
referral from primary care to UBC diagnosis, i.e., date of transurethral resection of the 
bladder tumor (TURBT). We plotted the cumulative proportion diagnosed by days from 
referral, noting that women experienced slightly shorter waiting times compared to men 
(Figure 12). More strikingly, only 43% and 48% of the men and women, respectively 
underwent TURBT within 22 days from referral, a strong recommendation according to 
Swedish guidelines (124).  
As a sensitivity analysis, we explored the interaction between sex and a subset of prognostic 
factors in MIBC (Table 10). We found the effect of sex to be relatively stable across age 
groups, educational level, comorbidity, and N stage. There was no evidence of a superior 
model fit compared to the fully adjusted model without the interaction term. T stage was the 
only exception and the excess female mortality was driven by T4 tumors. This finding urged 
us to stratify survival analysis of MIBC into T2, T3, and T4, discovering that women 
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diagnosed with non-metastasized T4 UBC had close to the same mortality as primarily 
metastasized UBC!  
Table 10. Adjusted female-to-male hazard ratios (HRs) with 95% confidence intervals (CIs), exploring interaction between 
sex and selected covariates and comparing model fit (p-value) to the fully adjusted original model (aHR2 in table 3, study III) 
in muscle invasive bladder cancer. 
  HR 95% CI   p-value 
Age groups      
18-59 1.24 0.97 1.59   
60-69 1.13 0.95 1.34   
70-79 1.19 1.05 1.36   
80-89 1.26 1.12 1.43  0.7211 
Educational level      
low 1.28 1.15 1.42   
medium 1.20 1.05 1.38   
high 1.10 0.88 1.37   
missing 0.90 0.65 1.25  0.1503 
Charlson Comorbidity Index     
0 1.19 1.07 1.32   
1 1.26 1.07 1.48   
2 1.34 1.09 1.66   
3+ 1.13 0.90 1.43  0.6367 
T stage      
T2 1.17 1.06 1.30   
T3 1.09 0.93 1.26   
T4 1.59 1.33 1.90  0.0028 
N stage      
N0 1.22 1.08 1.39   
N+ 1.26 1.03 1.54   
NX 1.19 1.07 1.33   0.8858 
 
It has been hypothesized that UBC tumor behavior is more aggressive in women and that sex 
differences in tumor biology underlie the adverse stage distribution and poorer UBC survival 
in women. We therefore decided to explore recurrence-free and progression-free survival in 
men and women diagnosed with NMIBC by plotting Kaplan-Meier survival curves (Figure 
13). This resulted in essentially overlapping curves and did not provide any evidence sex 
difference in non-muscle invasive UBC tumor biology. 
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Figure 13. Recurrence- and progression-free survival in men and women diagnosed with non-muscle invasive (T0 Tis Ta T1) 
urothelial bladder cancer and by risk group. 
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4.4 STUDY IV 
Since both male sex and tall body stature are associated with increased cancer risk and since 
men are taller than women, we decided to apply mediation analysis to explore to what extent 
body height can explain the excess cancer risk in men. The cancer-free survival in men and 
women was compared using age as the underlying time scale. Cancer-free survival time was 
counted from date of first adult (age ≥18) height measurement to date of cancer diagnosis. All 
models were adjusted for birth year and educational level. See 3.2.4 Causal inference on 
time-to-event outcomes for a detailed background to the methodology.  
Our main results are presented in the attached manuscript, study IV panel plot E (205). This 
figure is restricted to cancer sites that were found to be both more common in men as well as 
associated with increased body height. The proportion of the excess cancer risk in men 
explained by taller body stature ranged from 0.5% (laryngeal) to 100% (salivary gland, colon, 
melanoma, AML).The following tables and figures provide additional support and guidance 
to how and why we ended up with the final results.  
From panel plot B and C (study IV) it is clear that men are taller than women and that height 
has increased over calendar time in both sexes. We additionally wanted to assess whether 
height is associated with socioeconomic status (i.e., educational level) and if this relationship 
is consistent over calendar time. Mean height by sex and educational level was subsequently 
plotted over birth year 1900-1992 (Figure 14). Aside from instable estimates due to few 
individuals in the oldest cohort born before year 1910, we observed a remarkable consistency 
where the most highly educated men and women were approximately 5 cm taller than the 
least educated across birth year. 
Figure 14. Mean body height (cm) in men and women over year of birth, by educational level. 
 
 
Table 11 provides an overview of numbers and percentages of men and women diagnosed 
with cancer, male-to-female hazard ratios (HRs), and relative risk (RR) of cancer per 10 cm 
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height increase in both sexes, both estimates adjusted for birth year and educational level. Out 
of 39 cancer sites, men were at significantly increased risk of 33, compared to women. The 
only exceptions were biliary, anal, lung adenocarcinoma, meningeal, and both subtypes of 
thyroid cancer. Most malignancies were also found to be associated with height, whereof 27 
statistically significant. 
Table 11. Numbers (n) and percentages (%) of men and women, male-to-female hazard ratio (HR), and relative cancer risk 
(RR) per 10 centimeter height increase, 95% confidence interval (CI), both estimates adjusted for birth year and education.  
Cancer site 
  Men Women   Male-to-female   Men and women   
 n % n %  HR [95% CI]  RR [95% CI]   
Lip  1048 63 619 37  1.94 [1.75,2.14]  1.06 [ 0.98 , 1.15 ] 
Tongue  1167 61 751 39  1.61 [1.46,1.76]  0.98 [ 0.92 , 1.06 ] 
Salivary glands  657 55 539 45  1.25 [1.12,1.41]  1.25 [ 1.14 , 1.37 ] 
Other oral cavity  1140 56 906 44  1.35 [1.24,1.48]  0.97 [ 0.90 , 1.04 ] 
Pharyngeal  920 74 325 26  2.92 [2.57,3.32]  0.91 [ 0.83 , 1.00 ] 
Tonsillar   1215 74 422 26   2.91 [2.61,3.25]   1.10 [ 1.02 , 1.19 ] 
Esophageal ADC  1561 85 274 15  6.38 [5.61,7.26]  1.04 [ 0.97 , 1.12 ] 
Esophageal SCC  1189 65 651 35  2.04 [1.85,2.25]  1.06 [ 0.98 , 1.14 ] 
Gastric  5988 63 3452 37  1.97 [1.89,2.05]  0.94 [ 0.91 , 0.97 ] 
Hepatic  1827 71 751 29  2.70 [2.48,2.94]  0.97 [ 0.91 , 1.03 ] 
Biliary  1689 42 2354 58  0.79 [0.74,0.84]  1.14 [ 1.09 , 1.20 ] 
Pancreatic  4475 52 4220 49  1.15 [1.10,1.20]  1.11 [ 1.07 , 1.15 ] 
Small intestine   1524 57 1144 43   1.44 [1.33,1.55]   1.15 [ 1.08 , 1.22 ] 
Colon  19236 51 18274 49  1.18 [1.16,1.21]  1.18 [ 1.16 , 1.20 ] 
Rectal  12363 60 8390 40  1.64 [1.59,1.68]  1.10 [ 1.08 , 1.13 ] 
Anal   449 31 1021 70   0.47 [0.42,0.53]   1.22 [ 1.12 , 1.33 ] 
Nasal  434 60 289 40  1.59 [1.37,1.85]  1.11 [ 0.99 , 1.25 ] 
Laryngeal  1772 85 318 15  6.08 [5.39,6.85]  1.02 [ 0.95 , 1.09 ] 
Lung (all)  17049 54 14686 46  1.28 [1.25,1.30]  1.09 [ 1.07 , 1.11 ] 
Lung SCC  4316 66 2242 34  2.19 [2.08,2.30]  1.04 [ 1.00 , 1.09 ] 
Lung ADC  6345 48 7001 53  1.00 [0.96,1.03]  1.11 [ 1.07 , 1.14 ] 
SCLC  2363 52 2169 48  1.20 [1.13,1.27]  1.08 [ 1.03 , 1.14 ] 
Lung (other)  3983 54 3406 46  1.28 [1.22,1.34]  1.11 [ 1.07 , 1.15 ] 
Pleural   1074 85 191 15   6.28 [5.38,7.32]   1.20 [ 1.10 , 1.32 ] 
Urothelial  20316 75 6684 25  3.49 [3.39,3.58]  1.10 [ 1.07 , 1.12 ] 
Renal   6405 62 3856 38   1.78 [1.71,1.85]   1.23 [ 1.19 , 1.27 ] 
Melanoma  15392 51 14721 49  1.06 [1.03,1.08]  1.31 [ 1.29 , 1.34 ] 
Skin  17232 59 11824 41  1.74 [1.70,1.78]  1.24 [ 1.22 , 1.27 ] 
Brain  3229 62 1988 38  1.59 [1.50,1.68]  1.19 [ 1.14 , 1.24 ] 
Meningeal  1728 29 4242 71  0.40 [0.38,0.43]  1.03 [ 0.99 , 1.08 ] 
Thyroid well diff  1154 28 2956 72  0.35 [0.32,0.37]  1.20 [ 1.14 , 1.26 ] 
Thyroid anaplastic 206 41 295 59   0.70 [0.59,0.84]   1.26 [ 1.09 , 1.46 ] 
NHL  10353 58 7544 42  1.47 [1.43,1.52]  1.16 [ 1.13 , 1.19 ] 
CLL  3198 63 1906 37  1.87 [1.77,1.98]  1.22 [ 1.17 , 1.28 ] 
Hodgkin  1584 64 885 36  1.35 [1.24,1.47]  1.21 [ 1.14 , 1.29 ] 
Myeloma  3719 57 2759 43  1.50 [1.43,1.58]  1.12 [ 1.07 , 1.16 ] 
ALL  459 62 284 38  1.41 [1.21,1.64]  1.04 [ 0.92 , 1.16 ] 
AML  1759 54 1518 46  1.23 [1.15,1.32]  1.27 [ 1.20 , 1.34 ] 
CML   726 59 502 41   1.38 [1.23,1.54]   1.11 [ 1.01 , 1.21 ] 
 
The regression coefficient method applied to estimate the proportion of the excess cancer risk 
in men explained by height, relies on multiple assumptions, see section 3.2.4 Causal 
inference on time-to-event outcomes, and among these the assumption of proportional 
hazards. We applied flexible parametric models allowing for age-varying effects of sex to test 
this assumption as well as to illustrate the cancer-free survival proportion in men (S1M1) and 
women (S0M0) over adult age for cancer sites associated with male sex and tall body stature. 
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In addition to the actual cancer-free survival proportions, we plotted the counterfactual 
survival in men at women’s height (S1M0) and the counterfactual survival in women at 
men’s height (S0M1) and estimated the proportion of the excess cancer risk in men explained 
by height (PE) at age 90, see 3.2.2 Flexible parametric models for a description of the 
methodology.  
Figure 15. Cancer-free survival proportion in women, S0M0; men, S1M1; men at women's height, S1M0; women at men’s 
height, S0M1; and the proportion of the excess cancer risk in men explained by height at age 90, PE. 
 
Figure 15 exemplifies 8 male-predominated malignancies, covering different anatomical 
tracts and illustrating various effects of the height-standardization. The proportions explained 
by height, estimated using flexible parametric models allowing for time-varying effects of 
sex, were identical or at least very close to those estimated using the, unadjusted, regression 
coefficient method (not presented). Tonsillar, pancreatic, rectal, renal cancer, and non-
Hodgkin lymphoma were all more common in men across age, and a substantial proportion 
of the excess male cancer risk at age 90 (26-100%) was explained by height. The effect of the 
height standardization was evaluated by assessing a potential shift of the counterfactual male 
cancer-free survival function (S1M0) compared to the actual (S1M1). 
Laryngeal cancer was found to be 6 times more common in men but the relative risk did not 
increase significantly with height (Table 11). Consequently, height standardization did not 
alter the cancer-free survival function in neither men nor women, and none of the excess male 
 54 
laryngeal cancer risk was thus explained by body height (Figure 15). In pancreatic cancer, 
height-standardization caused the counterfactual survival in men at women’s height (S1M0) 
to practically overlay the actual cancer-free survival in women (S0M0). Body height thus 
accounted for 100% of the excess pancreatic cancer risk in men. Men are at a higher risk for 
malignant melanoma at age 90, but melanoma is more common in young women than men. 
This results in crossing actual cancer-free survival functions in men (S1M1) and women 
(S0M0) suggesting a potential problem when interpreting the output from Cox proportional 
hazards regression models.   
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 DISCUSSION 
A balanced report of strengths, limitations and weaknesses, together with comparisons of 
ours with previously published results, can be found in the attached publications and 
manuscripts, studies I-IV. 
5.1 SEX AND CANCER RISK 
In studies I and IV, both large population-based cohort studies based on Swedish Cancer 
Register data, we outlined the persistent excess cancer risk in men and investigated whether 
this can be explained be attained height. We found that male sex is a consistent risk factor for 
34 of 39 studied malignancies affecting both men and women. The excess risk in men 
decreases over time in cancers with established, strong, environmental risk factors but 
remains elevated for a majority of sites. Most cancers display a similar age pattern where the 
excess cancer risk in men culminates when cancer incidence peaks, around the age of 70. The 
population attributable risk percent estimates confirmed that biological and/or environmental 
factors related to sex account for a substantial fraction of all incident cancer cases. Moreover, 
we were able to demonstrate that a substantial proportion of the excess cancer risk in men is 
mediated by body height. The height effect was most consistent and pronounced in cancer 
sites with few or no known environmental risk factors and less so in sites with an established 
association to smoking and/or alcohol. 
No one can argue against the fact that a large proportion of the observed sex differences in 
cancer incidence is due to a historically disproportionate exposure to mainly tobacco smoking 
(respiratory tract and esophageal squamous cell), but also alcohol (oral cavity, pharynx, 
larynx, and liver) and/or occupational carcinogens (pleura, urothelial). The proportion of 
daily smokers is however larger in Swedish women compared to men since the late 1980s. 
By that, excess smoking in men cannot fully account for the prevailing male predominance in 
these sites, even when considering birth cohort effects and latency periods. Moreover, 
environmental factors offer no explanation to the consistent excess male cancer risk in sites 
with weak or largely no known risk factors (e.g., small intestine, CNS, and hematological 
malignancies) nor in sites where environmental carcinogens contribute moderately. The 
consistency across anatomical tract, calendar time, and geographical region, rather indicates 
underlying innate, biological processes spanning over immune function, hormonal regulation, 
gene expression, response to oxidative damage, metabolic, and/or anatomic mechanisms (14, 
32, 120). The increasing male-to-female cumulative incidence over age, does not necessarily 
reflect different biology in different age groups, but could also imply increasing life-time 
cumulative effects. Exceptions do however always exist, and the deviant age pattern observed 
in tumors originating from the salivary glands, stomach, colon, and malignant melanoma, is 
highly interesting and could possibly reflect the effect of female sex hormones or other 
factors related to the female reproductive age (120). 
Recognition of the intimate interplay between immunological processes and carcinogenesis is 
rapidly advancing. This research area focus on host protector properties and/or interaction 
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between the immune system and tumor cells (33, 34). Immunological processes act 
differently in men and women resulting in sex differences in risk of and outcomes from not 
only autoimmune conditions (more common in women), infections, (higher vulnerability in 
men), but conceivably also malignant diseases (26, 28-31). Immunological mechanisms, 
including a reduced innate and adaptive immune function in men, are likely to at least partly 
account for sex differences in cancer risk as well as survival (29, 33, 34, 206). Among 
multiple possible mechanisms women seem to have an increased number of activated T cells 
and a higher cytotoxic T cell activity in peripheral blood while men express higher levels of 
regulatory T cells (28-30, 206). Immunologic mechanisms may indeed act differently in 
different tumor types. Promotor elements of several immune-related genes have androgen and 
estrogen response elements, perhaps offering an explanation to some tumors being more 
common in young women (28-31, 33, 34, 206).  
Another not well-investigated hypothesis is the relationship between sex, cancer risk, and 
height (161, 163). Somatic cell division and DNA replication are continuously ongoing 
processes to maintain tissue homeostasis. Somatic driver mutations in cancer occur 
spontaneously or are induced by carcinogens in the environment. It is well-established that 
cancer risk in different organs diverges radically, but it was not until recently suggested that 
this is driven by stem cell number and turnover rate within tissue, predicting the accumulation 
of mutations in proto-oncogenes (32, 153, 158, 161). It has been estimated that only 
approximately one third of the variation in cancer risk between different organs is explained 
by environmental and/or hereditary risk factors (32, 159). The remaining variation is an effect 
of randomly acquired deleterious mutations (32, 159). The positive association between tall 
stature and cancer rate in both sexes supports this concept (143, 151, 152, 161), while the 
absent relationship between body size and cancer risk comparing mammal species (Peto’s 
paradox) is contradictory (207). The later phenomenon probably has basic, evolutionary 
explanations and it has been shown that larger, long-lived animals have evolved mechanisms 
to suppress carcinogenesis. The African elephant, for example, have 20 copies of the tumor 
suppressor gene TP53, while the human genome typically harbors one (208). Within species, 
the idea of increasing cancer risk with stem cell numbers to target (body size) and lifespan 
seems to hold. Larger body size in men is probably a trade-off between increased access to 
resources, mating, and predator avoidance and an increased cancer risk with age (209). In 
mammals, body size is dependent on cell number, i.e., larger individuals consists of more and 
not larger cells (210). An exception is tissue consisting of slowly dividing cells, like nerve, 
muscle, and white fat, which seems to increase in volume. Malignant tumors originating from 
these types of tissue are however very rare. (210), Body size, in this context, is not to be 
mixed up with overweight and obesity. The latter implies excessive body fat and other 
causative pathways to increased cancer risk.  
Previous studies on height and cancer have been small and presented discrepant results due to 
limited number of incident cancer cases and consequently low statistical power (143, 151, 
152). To our knowledge, only one has studied to what extent body height can explain the 
association between male sex and cancer risk (163). Study IV is, to our knowledge, by far the 
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largest to investigate the relationship between sex, cancer risk, and height (163, 205). The 
population-based approach and individual-level record linkage of multiple nationwide 
registers, yielded high-quality data on incident cancers as well as an unbiased long-term 
follow-up. None of the previously performed studies on height and cancer had enough data 
and/or the same level of granularity to categorize malignancies into equally many subtypes. 
Some were based solely on one sex and/or cancer mortality rates in the population (143, 145, 
147, 151-153). Study IV is moreover the first to use state-of-the-art mediation analysis in a 
time-to-event setting for this specific research question (163, 181, 205).  
The notion of cumulative cell divisions and cancer risk is consistent with the multistage 
model of carcinogenesis and the general cancer age-incidence pattern (153, 157, 159-161). 
This concept is however not uncontroversial. Other research groups have estimated that 
environmental factors account for more than 90% of all incident cancer cases, even in sites 
without established associations to environmental carcinogens, like osteosarcoma (> 81%) 
and glioblastoma (> 95% ) (160, 211). The correlation between height and stem cell number 
probably varies between organs and cell types (161). Together with various environmental 
risk factors this offers an explanation to the discrepant effect of height in malignancies with 
different anatomical and histological origin. Lung cancer is an interesting example, basically 
all subtypes are strongly associated with smoking, but somewhat to lesser extent in lung 
adenocarcinoma which also happens to be the subtype with the strongest association to 
height. Small intestine cancer is very rare (only 2,668 cases in our cohort) while colon cancer 
is one of the most common malignancies (37,510 cases), the RR per 10 cm height increase is 
however very similar, 15% and 18%, respectively. The disparate cancer incidence in small 
intestinal and colon mucosa, despite similar exposure to carcinogens from dietary intake, is 
believed to be due to a higher stem cell turnover rate, in the latter (32). Alternative 
explanations to the height-cancer association, than through cell number, have been proposed. 
Genetic determinants of height may also be directly associated with cancer. Environmental 
exposure, like adult caloric intake due to a higher energy expenditure and/or basal metabolic 
rate in taller individuals may accelerate cancer risk (151). Malnutrition during growth results 
in stunting and conceivably lower levels of insulin-like growth factors, which are suspected 
to speed carcinogenesis (152, 158). There is seldom one single answer to complex questions 
and the drivers behind the observed relationship between height and cancer can obviously 
vary and interact differently over time, sex, and by cancer site. 
The strong biological effect of attained educational level is appealing. It was a pre-specified 
hypothesis to use educational level as a proxy for socioeconomic confounders associated with 
cancer risk and height. We did however not expect that low education is such a strong risk 
factor for basically every cancer site (results not presented). This association is most probably 
driven by various exposure to environmental risk factors due to behavioral differences in 
educational groups, but the topic deserves to be studied further (57). The strength and 
consistency of association between educational level and height was also unexpected (155, 
156, 212). Those with the highest attained educational level was found to be approximately 5 
cm taller than those with the lowest education, in men and women as well as over birth 
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cohort. Adult stature is mainly determined by two factors; genes and malnutrition during 
growth in uterus as well as in childhood and adolescence (155, 156, 212). Even slightly 
preterm children are believed to develop a shorter adult stature and but also to have a lower 
probability of attaining higher education, offering a feasible hypothesis to this conundrum 
(213). Maternal risk factors for preterm labor include concurrent disease, low education and 
income, emotional distress, and substance abuse, all possible contributors to a lower 
education in their offspring (214).  
5.2 SEX AND CANCER SURVIVAL 
In study I we aimed to delineate sex differences in cancer survival for all non-sex-specific 
cancers and in study II and III we searched for possible explanations to the observed survival 
inequality in non-small cell lung cancer (NSCLC) and urothelial bladder cancer (UBC), 
respectively. We found that male sex is a persistent negative prognostic factor in malignant 
disease (study I). But, with the exception of lung cancer, malignant melanoma, non-Hodgkin 
and Hodgkin lymphoma and CLL, sex differences in survival have diminished and/or evened 
out over calendar time. Biliary and urothelial cancer represent intriguing exceptions and are 
the only two sites were women do consistently worse. When investigating NSCLC closer 
(study II), men were found to have a consistently poorer prognosis across cell type and stage 
group that remained unaltered after careful adjustments for a range of clinicopathological and 
socioeconomic prognostic factors. In UBC (study III), the female survival disadvantage was 
limited to muscle invasive tumors and only evident within the first two years from diagnosis. 
The increased bladder cancer mortality in women with muscle invasive tumors was robust 
following adjustments for multiple prognostic factors. 
Disentangling potential, underlying causes to the observed sex differences in cancer survival 
is indeed challenging and multiple interacting factors must be considered. The inconsistent 
pattern across calendar time suggests environmental and/or behavioral factors that have 
equalized over the years (215). In both NSCLC and UBC we found that men had a higher 
comorbidity burden. This is, at least partly, likely to be driven by a higher tobacco and 
alcohol consumption in men. We did find a smaller proportion of never-smokers in men 
diagnosed with NSCLC, supporting this notion. The rationale behind the higher smoking 
prevalence in male patients while the proportion of smokers in the Swedish population is 
higher in women than men, is not fully understood. But this could be a birth cohort 
phenomenon indicative of latency and/or reflecting different tumor biology in men and 
women. Smoking in itself affects lung capacity, wound healing, and reduces the chance of 
undergoing and surviving, not only pulmonary, but all major surgery, due to risks associated 
with anesthesia but also of postoperative morbidity and mortality. Comorbidity, discussed in 
detail in previous sections, affects the ability to undergo and tolerate intensive cancer therapy, 
an important predictor of long-term survival. We found no sex differences in the clinical 
management, including treatment, of NSCLC and UBC, after adjusting for factors like age, 
comorbidity, and (in NSCLC) performance status and smoking history. Comorbidity is 
however complex to measure (see 3.2.3 Measuring comorbidity) and self-reported smoking 
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habits at one time point is an unreliable measure and does not capture, for example, pack-
years. Even if men and women have the same likelihood of undergoing cancer surgery, 
different smoking history and comorbidity burden may alter their chance of recovering from 
the procedure.  
In NSCLC we found an adverse stage distribution in men, while the opposite was noted in 
UBC. The former could reflect a common belief in the medical community corroborated by 
results from qualitative studies, that men, in general, endure a higher threshold to seek 
medical attention (67-69). Despite higher age and comorbidity burden in men, men and 
women diagnosed with NSCLC where found to have an equivalent health care utilization, 
measured as number of outpatient visits, supporting an increased health awareness in women. 
The excess mortality in women diagnosed with UBC is traditionally believed to be a result of 
the first early symptoms of UBC, i.e., visible hematuria, being dismissed by female patients 
as well as their general practitioners. We did not find any evidence of an unequal clinical 
management including waiting times of men and women diagnosed with NSCLC nor UBC 
after referral to specialist care. This finding does however not exclude previous patient’s 
and/or doctor’s delay, in the primary care setting. According to the few studies on gender 
inequality in health care that exist, men seem to be more likely to undergo curative cancer 
surgery, receive up-to-date pharmaceuticals in cardiovascular disease, and adequate 
management of myocardial infarctions (70-72, 216). Stage is a very strong, independent 
prognostic factor. Despite the careful handling and adjustments for sex differences in stage, 
and (in NSCLC) also primary tumor location, we most probably have an issue with residual 
confounding, i.e., more advanced stage within reported stage category.   
Sex differences in tumor biology causing more aggressive tumor behavior in men with 
NSCLC and women with UBC, have been suggested. Estrogen, the primary female sex 
hormone, has been suggested to improve cancer prognosis in women in reproductive age 
through inhibitory effects on distant metastasizing (46). And testosterone, the primary male 
sex hormone, has been hypothesized to drive cancer aggressiveness (64). We had limited data 
to explore biomarkers of tumor behavior in our material. Pulmonary adenocarcinomas in 
women more often harbor certain genetic alterations (activating EGFR mutations and ALK 
translocations) predicting response to tyrosine-kinase inhibitors but also independently, 
indicative of a more favorable prognosis. The very same genetic alterations have been shown 
to be more common in Asian and non-smoking lung adenocarcinoma patients. EGFR 
mutational status was recorded in patients diagnosed in 2010-2016, whereof approximately 
55-60% were tested. We found that activating EGFR mutations were more common in 
women, compared to men. In a subgroup analysis of lung adenocarcinoma patients tested for 
EGFR, we additionally adjusted for EGFR mutational status and found that the male excess 
mortality diminished slightly. The interpretation of this finding is hampered by small 
numbers and short follow-up in this subgroup. The observed sex discrepancies in age 
distribution, smoking history, EGFR status, and performed diagnostics (thoracentesis and 
PET scans) indicative of variant disease spread, together with the robust superior female 
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survival across stage group, following adjustments, support the notion of sex differences in 
lung adenocarcinoma tumor biology.  
Non-muscle invasive UBC in women were slightly more often WHO low-grade, indicating 
lower risk of recurrence and/or progression. In addition to bladder cancer-specific survival 
proportions, we plotted recurrence- and progression-free survival over follow-up in men and 
women with non-muscle invasive UBC and found no evidence of faster advancing bladder 
tumors in women. Female UBC cases were discussed at multidisciplinary conferences and 
women with muscle invasive tumors underwent radical cystectomy at high-volume hospitals 
slightly more frequently, even after adjustments for stage. This indicates awareness of the 
poorer prognosis and/or expectations of more complications in women, amongst clinicians 
working with UBC. Exploring the interaction between sex and selected covariates in muscle 
invasive UBC led to a remarkable finding: women with T4 tumors had close to the same 
mortality as patients with primarily metastasized UBC. We used information on T stage from 
histopathological examination of diagnostic TURBT specimens and clinical N stage from 
radiological examinations, both can diverge largely from pathological staging (217). T4b 
bladder tumors (extension to pelvic wall and/or adjacent organs other than prostate, vagina, or 
uterus) are commonly considered unresectable. We do not know if T4b tumors are more 
common in women. Comparing clinical and, postoperative, pathological T, but also N, stage 
in men and women could help us understand the drivers behind the excess UBC mortality in 
women with T4 tumors. Studying urinary bladder physiology in men and women in relation 
to tumor invasion, T stage, and conceivably also surgical complications, could also enlighten 
this finding. In conclusion, we found no evidence of a more aggressive UBC tumor behavior 
in women, our results rather point towards sex differences regarding the only, potentially 
curative treatment of muscle-invasive UBC, namely radical cystectomy. 
NSCLC and UBC are both malignancies where modern immunotherapy is revolutionizing 
cancer prognosis among responders. Checkpoint inhibitors were not approved for use in 
neither of these two malignancies during the studied time period. Studies on immunotherapy 
in NSCLC and UBC have so far mainly consisted of comparisons with chemotherapy in the 
palliative situation. From our results, we know that in the “standard” treatment situation 
(including best supportive care) women with advanced stage non-small cell lung (both cell 
types) have a survival advantage while men and women with advanced bladder cancer seem 
to do equally poorly. Meta-analyses studying potential sex differences in beneficial effect or 
efficacy from immunotherapy have demonstrated conflicting results (206, 218, 219). Studies 
demonstrating effect estimates favoring men have in general been based on study cohorts 
composed of less than 20% women (219). Performed meta-analysis have relied on the 
presented clinical trial hazard ratios and not on patient-level data. Moreover, the focus has 
been on comparing sex-specific hazard ratios comparing traditional treatment (chemotherapy) 
and immunotherapy, not taking the general female cancer survival advantage into account 
(218, 219). As discussed previously, cancer immunology does not only cover therapeutic 
advances, but also the role of the immune system in tumor progression and formation of 
metastasis (33, 220). This includes immunosuppressive components in the tumor 
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microenvironment like down-modulation of antigen presentation, recruitment of suppressor 
immune cells, and production of immunosuppressive factors. Many of these pathways have 
not only been shown to differ between the sexes but are also prognostic of cancer outcome 
and could provide an answer to the consistently superior female survival in most 
malignancies (28, 30, 33, 34, 206).  
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 CONCLUSIONS 
Sex differences in cancer risk 
 Male sex is an independent risk factor for a majority of common-site cancers and 
the fraction of cases attributable to factors related to male sex is considerable. 
 The consistency over time and age indicates underlying biological drivers.  
 A fair proportion of the excess cancer risk in men is explained by sex differences 
in body height, strengthening the evidence behind the stochastic effects of DNA 
replication with increasing cell numbers on cancer risk.  
 Preventive measures to reduce the excess male cancer risk in sites where a 
majority of the effect is mediated through body height are not worthwhile and 
resources are better spent elsewhere. 
Sex differences in cancer survival 
 Male sex is associated with poorer cancer prognosis, but the male survival 
disadvantage has leveled out over time for a majority of cancer sites. 
 Our findings suggest fundamental, but modifiable, behavioral gender differences 
underlying the poorer cancer outcome in men. 
Sex differences in non-small cell lung cancer survival 
 The female non-small cell lung cancer survival advantage is persistent over 
calendar time.  
 This effect is strongest and most consistent in pulmonary adenocarcinoma and 
robust to adjustments for multiple clinicopathological factors, including stage, at 
diagnosis. 
 Women with lung adenocarcinoma are younger, more often never-smokers, and 
harbor activating EGFR mutations more frequently, compared to men.  
 These findings suggest sex differences in tumor biology, contributing to the 
female survival advantage in lung adenocarcinoma. 
Sex differences in urothelial bladder cancer survival  
 The excess bladder cancer mortality in women is limited to muscle-invasive but 
not yet metastasized tumors and is largely driven by T4 tumors, at diagnosis. 
 The female excess mortality is only noticeable within two years from diagnosis.  
 This indicates sex differences in treatment, including complications, of muscle-
invasive bladder cancer. 
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 FUTURE PERSPECTIVES 
In the era of personalized medicine it is revolting that such a simple variable as patient or cell 
sex (in vitro studies) is not consistently reported. Evidence to differential treatment 
tolerability and long- and short-term response in men and women are momentous and costs 
for newly developed medicines in health care are growing exponentially. This thesis is 
mainly focusing on and investigating the effect of sex as a biological variable on cancer risk 
and survival. But the pathways through which the effect of sex are executed are most 
probably reflected by complex interactions between genetic, anatomic, hormone, 
immunologic, and environment factors, where the latter includes gender. Gender research in 
medicine has mainly focused on women’s right to equal access to and utilization of health 
care resources. Our main conclusion, from a cancer preventive and treatment perspective, is 
that men do substantially worse compared to women.  
Studying the exceptions to the general pattern is attractive and can occasionally generate new 
hypotheses. The excess risk of anal cancer in women is believed to be due to HPV infection, 
and the effect of the national HPV vaccination program on anal cancer incidence in Sweden 
will be disclosed in the near future. The remaining female-dominated cancer sites; biliary 
tract, meninges, and thyroid, deserves to be studied further. Meningioma and thyroid cancer 
are of benign character and over-diagnosis of subclinical disease that will never cause 
symptoms due to health seeking behavior and/or investigations of other conditions, like 
autoimmune thyroid disease in women, are possible explanations. Biliary cancer is rare but 
aggressive, and survival has remained very poor. Except for in young ages when men 
dominate, biliary cancer is more common in women. The most well-known risk factor in 
young, western populations is primary sclerosing cholangitis associated with inflammatory 
bowel disease. This relationship and the possible increasing trend in young adults in Sweden 
(results not presented) deserves to be studied further as well as the underlying drivers behind 
the poorer survival in women. An aberrant incidence pattern over age was observed for 
tumors originating from the salivary glands, stomach, colon, lung cancer (all major subtypes 
except squamous cell), and malignant melanoma of the skin. These sites were all found to be 
more common in women before menopause. The underlying reasons for this phenomenon 
deserve to be studied further. Pregnancy is a state of temporary immunosuppression in 
women potentially triggering carcinogenesis. Exploring incidence patterns in relation to 
pregnancy in cancers that are more common in women compared to men during female 
reproductive age could provide a clue to this inconsistency.   
The association between height and cancer risk is highly interesting and deserves to be 
studied further. The continuous increase in body height in Swedish men and women during 
the 20th century are most probably due to improved living conditions. This has resulted in a 
decreased prevalence of diseases and conditions during pregnancy, childhood and 
adolescence, affecting attained adult body height through malnutrition during periods of 
growth. This is supported by the notion that the height increase seems to have flattened out in 
individuals born in the 1980s and 1990s. What predicts an individual’s attained height in 
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Sweden today is consequently mainly the target height of your parents, i.e., genetic, and not 
environmental factors. One way to further test the hypothesis of the stochastic effects of DNA 
replication with increasing cell numbers on cancer risk would be to study the association 
between cancer and known genetic determinants of height using existent genome-wide 
association study datasets. 
It is estimated that tobacco smoking accounts for half of all incident cases of UBC. Despite 
this, UBC incidence continues to increase in both sexes and has remained consistently 3-4 
times higher in men. UBC is a malignancy of the elderly, indicating cumulative carcinogen 
exposure, i.e., a long latency period. Urinary bladder function is commonly impaired in men 
through benign prostatic hyperplasia causing urinary retention and, in the long run, bladder 
muscle wall thickening. Women more often suffer from overactive bladder, aggravated by 
dry mucous membranes and repeated lower urinary tract infections after menopause and/or 
pelvic floor impairment after pregnancy and childbirth. Benign prostate hyperplasia, through 
prolonged exposure to urine carcinogens, could potentially account for the excess UBC risk 
and, through bladder wall thickening, contribute to the superior survival, in men. Benign 
prostate hyperplasia does seem to increase UBC risk, but it is not known to what extent this 
accounts for the excess risk in men compared to women (221). Tumor invasion into the 
bladder wall ought to take longer in case of bladder wall thickening, resulting in less 
advanced stage at diagnosis in men. Delicate bladder walls in women might increase 
complication rates after radical cystectomy. Studying sex differences in muscle-invasive 
tumors closer and with a special regard to preoperative treatment and radical cystectomy 
details, such as duration, type of urinary diversion, lymph node dissection, clinical and 
pathological staging, and short- and long-term surgical complications, could improve our 
understanding of the female survival disadvantage. 
Personalized cancer medicine involves genetic testing of cancer and normal cells to achieve 
more effective, customized strategies for cancer prevention, screening, and treatment. Genetic 
and/or hormonal differences in men and women have been shown to affect elimination rate of 
anticancer drugs (52, 53). The clearance of chemotherapy but also monoclonal antibodies 
seems to be more effective in men compared to women (52, 53). In the routine clinical 
setting, these drugs are still identically dosed and administered, using body surface area rather 
than drug elimination rate, in men and women. This leads to unpredictable effect variation 
where overdosing probably accounts for the repeated reports of higher chemotherapy toxicity 
rates in women, while unrecognized underdosing may underlie poorer response rates and 
cancer survival in men (53). Clinical cancer studies should collect data on pharmacokinetics, 
like expression of metabolic enzymes and transporters in liver and kidney, which probably 
differs between anticancer substances and protocols, to form the basis of future dosing 
algorithms. Retrospective subgroup analyses on already performed clinical studies containing 
information on side effects, dose reductions, and short- and long-term cancer patient 
outcome, could readily support clinical decision making and prompt dose-escalations or dose-
reductions in patients experiencing unexpectedly low or high toxicity, respectively, regardless 
of sex. 
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The high cost of and inconsistent response to immunotherapeutic drugs have urged a search 
for factors that predict treatment response. Various biomarkers have been proposed, including 
protein death-ligand 1, tumor mutational burden, microsatellite instability, and tumor-
infiltrating lymphocytes (216). Many of these tests have also been shown to be prognostic, 
regardless of therapy (216). To redo analyses stratified by sex on already existing datasets, 
could delineate if these alterations are more or less common in women and whether the 
strength of association to prognosis and/or response to immunotherapy differs between the 
sexes. In addition to a potential improvement of personalized medicine this could add 
valuable information on the underlying biological drivers behind sex differences in cancer 
risk as well as prognosis (191, 213, 214).  
Studies on amenable factors associated with disease risk and prognosis are simple and 
straightforward to motivate. But biological drives, like attained height and immune 
competence, can be equally interesting. Results from studies on sex differences in cancer risk 
and survival can enable us to guide limited health care resources to where they are most 
needed and have the greatest chance of postponing and/or reducing the number of 
preventable cancer deaths. Instead of focusing on men and women receiving the exact same 
management, we ought to aim towards treating men and women to achieve the most effective 
prevention of cancer death in both sexes. To accomplish this, we need to improve our 
knowledge of the determinants of sex on cancer risk and treatment outcome. Therefor patient 
sex should always be considered in studies on cancer risk and survival. 
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 SWEDISH SUMMARY 
Det är ett väletablerat faktum att män, jämfört kvinnor, har större risk att insjukna i de flesta 
cancerformer som drabbar bägge könen. Att män dessutom även har sämre prognos efter 
insjuknande i cancer är inte lika känt. Orsakerna till det först nämnda har traditionellt ansetts 
vara en högre exponering för cancerframkallande faktorer såsom tobaksrökning, alkohol, 
UV-strålning och kemikalier inom industri och verkstadsarbete. Könsskillnader i 
canceröverlevnad är styvmoderligt studerat, men en allmän uppfattning har varit att män 
söker vård i ett mer framskridet stadium där sjukdomen inte lika ofta går att bota. 
I studie I ville vi kartlägga könsskillnader i cancerrisk och -överlevnad över tid och ålder 
samt kvantifiera hur stor andel av alla cancerfall som kan förklaras av den manliga 
canceröverrisken. Med svenska cancerregisterdata identifierade vi 39 icke-könsspecifika 
tumörformer, diagnosticerade år 1970-2014, vid 15-84 års ålder. Med undantag för tumörer 
med en mycket stark koppling till rökning och/eller alkohol (luftvägar, huvud-hals, matstrupe 
och lever), kunde vi visa att den manliga överrisken är stabil över kalendertid. När vi 
studerade insjuknande över ålder var det tydligt att överrisken bland män var som störst i den 
åldersgrupp där cancerrisken i befolkningen kulminerar (65-75 år). Trender i överlevnad var 
inte lika slående och för flera tumörformer kunde vi konstatera att män och kvinnor numera 
har samma förväntade överlevnad. Sammantaget talar våra fynd för att något mer än 
miljöfaktorer ligger bakom den generellt ökade cancerrisken bland män. 
Canceröverlevnad är multifaktoriellt och det finns troligtvis inte en förklaringsmodell för alla 
tumörformer. Sannolikt spelar skillnader i beteende mellan män och kvinnor en viktig roll. 
För att på detaljnivå studera könsskillnader i överlevnad valde vi i studie II och III att 
fokusera på två vanliga tumörer; icke-småcellig lungcancer respektive cancer i urinblåsa. 
Svenska kvalitetsregisterdata länkade till flera andra populationsbaserade register gav oss 
detaljerad information om tumörtyp/-stadium, cancerbehandling, väntetider, samsjuklighet, 
socioekonomi, dödsorsak, med mera. 
Det är välkänt att kvinnor med icke-småcellig lungcancer har bättre prognos än män, 
orsakerna till detta är inte klarlagda. Icke-småcellig lungcancer kan delas upp i två olika 
celltyper; skivepitelcancer och adenocarcinom, där epidemiologi, behandling och prognos 
skiljer sig radikalt. Vi valde därför att analysera dessa två celltyper separat. Liksom tidigare 
studier på området, kunde vi konstatera att kvinnliga patienter har en generellt bättre 
överlevnad i alla stadier av sjukdomen, men detta var mest uppenbart bland de med lung-
adenocarcinom. Kvinnor i denna grupp var yngre, hade mindre samsjuklighet, högre 
utbildningsnivå och var oftare icke-rökare, jämfört med män. Vi hittade inga eller mycket 
små skillnader i klinisk handläggning; genomförda undersökningar, väntetider och 
behandling, mellan män och kvinnor. Våra resultat talar för skillnader i tumörbiologi mellan 
män och kvinnor med adenocarcinom i lunga. 
Urinblåstumörer är tre till fyra gånger vanligare bland män. Kvinnor har dock, till skillnad 
från de flesta andra tumörformer, sämre prognos. Det förstnämnda tros vara relaterat till 
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rökning och yrkesexponering för carcinogener. Orsakerna bakom den ojämlika 
blåscancerdödligheten är inte klarlagda, men tros bero på att kvinnor med synligt blod i 
urinen inte handläggs lika skyndsamt som män vilket leder till mer avancerade tumörstadium 
och sämre prognos. Ytligt växande tumörer i urinblåsa har en mycket god prognos och de 
flesta är botade efter lokalbehandling. Muskelinvasiv och metastaserad (spridd till andra 
organ) blåscancer har däremot ett aggressivt förlopp med förväntad 5-årsöverlevnad på 50 
respektive 5 %, vid optimal behandling. Vi valde därför att gruppera överlevnadsanalyserna i 
dessa tre stadier. Utöver att andelen kvinnor ökade med tumörens utbredningsgrad kunde vi 
inte hitta några tecken till ojämlik klinisk handläggning. Överdödligheten i blåscancer bland 
kvinnor var begränsad till de första två åren efter diagnos och sågs endast i subgruppen med 
muskelinvasiv, men ännu icke spridd, blåscancer. Skillnaderna kvarstod efter justering för en 
rad prognostiska faktorer. Sammantaget talar detta för skillnader i klinisk handläggning och 
behandling (radikal kirurgi) av män och kvinnor med muskelinvasiva tumörer. Den 
ogynnsamma stadiefördelningen och den uttalade mortaliteten bland kvinnor med potentiellt 
botbar muskelinvasiv blåscancer fordrar en ökad kännedom i befolkning och primärvård om 
att synligt blod i urinen är ett alarmsymptom på blåscancer som kräver omedelbar utredning 
på specialiserad enhet, även hos kvinnor. 
Flera studier har visat att längre individer har en förhöjd cancerrisk under livet. En stor andel 
av alla cancerfall beror antagligen inte på miljö- eller ärftliga faktorer, utan är en följd av 
slumpmässiga fel i arvsmassan (mutationer) som sker i samband med celldelning. Längre 
individer har fler celler och därmed fler celldelningar vilket skulle kunna förklara detta 
fenomen. I studie IV ville vi undersöka om canceröverrisken hos män kan förklaras av att 
män generellt är längre än kvinnor. Vi använde oss av data på vuxen kroppslängd hos drygt 
sex miljoner svenska män och kvinnor extraherade från pass-, mönstrings- och 
mödravårdsregistret, länkat till cancerregistret. Med nyutvecklad metodologi, tid-till-utfall 
mediationsanalys, kunde vi påvisa att kroppslängd spelar en avgörande roll för den förhöjda 
cancerrisken hos män för ett flertal av de undersökta cancertyperna. 
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